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 Iron is an enigmatic molecule – a divalent metal 
absolutely required for life, but toxic in excess. Because 
of this dual nature, iron trafficking within the cell is 
tightly regulated, with little free iron available in the 
cytosol. Iron entry into the cell is mediated through two 
distinct pathways, both of which utilize the Divalent Metal 
Transporter (DMT1), a twelve-transmembrane protein which is 
the only known iron importer in the cell. Dexras1 is a 
small G-protein regulated by glucocorticoids and neuronal 
nitric oxide synthase (nNOS). Using yeast-two-hybrid 
analysis, we have discovered that Dexras1 interacts with 
DMT1 via an adaptor protein, the Peripheral Benzodiazepine 
Receptor Associated Protein (PAP7). We have identified a 
novel signaling cascade in neurons whereby stimulation of 
glutamate-NMDA receptors activates nNOS, leading to S-
nitrosylation of Dexras1, which by its interaction with 
PAP7 and DMT1, physiologically induces iron uptake. We have 
also investigated whether misregulation of this pathway 
participates in NMDA-mediated neuronal excitoxicity. 
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PART 1: IRON 
Part 1.1: Iron Absorption 
 Iron is the most abundant metal in the body and is an 
essential cofactor for cytochromes, oxygen binding 
molecules, such as heme, and many other enzymes, including 
those involved in DNA and neurotransmitter synthesis 
(reviewed in [(Andrews, 1999; Donovan and Andrews, 2004; 
Hentze et al., 2004)]). As iron has a dual nature – 
necessary for life, but toxic in excess- it is tightly 
regulated within the cell and also in its uptake into the 
cell. Iron absorption is the sole mechanism by which iron 
stores in the body are regulated, as there is no known 
physiological mechanism for iron excretion (McCance and 
Widdowson, 1938). 
 Iron is taken up from the diet in two forms: inorganic 
non-heme iron or heme. 1-3 grams of iron is stored in the 
adult body, balanced between dietary uptake and loss (Muir 
and Hopfer, 1985). Non-heme iron is absorbed in the 
duodenum and upper jejunum (Donovan and Andrews, 2004), 
which is regulated by the levels of iron stores. At low 
levels, absorption is increased, while at high levels, 
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absorption is decreased.  The physical state of iron itself 
influences its absorption: at pH 7, ferrous (Fe2+) is 
converted into the insoluble ferric (Fe3+) state. Gastric 
acid lowers pH, thus enhancing solubility and uptake of Fe2+ 
by intestinal mucosal cells. Other factors which enhance 
absorption are ascorbate and citrate (Conrad and Umbreit, 
1993), while phytates, tannins and antacids inhibit 
absorption and other divalent metals, such as lead, cobalt, 
manganese and zinc are competitors for absorption.   
 Iron passes from the gut lumen through the apical and 
basolateral membrane of the enterocytes to reach the plasma 
membrane (Figure 1) (reviewed in [(Andrews, 1999; Hentze et 
al., 2004). Low pH dissolves ingested iron and facilitates 
the enzymatic reduction of ferric iron to ferrous iron at 
the apical surface via a brush border ferrireductase, Dcytb 
(Riedel et al., 1995).  Fe2+ is transported across the 
apical membrane into the enterocyte via the Divalent Metal 
Transporter (DMT-1, discussed later) (Cellier et al., 1995; 
Fleming et al., 1997) in a proton-coupled process. Once 
inside the enterocyte, the iron has two fates: it can 
either be stored in ferritin if body iron stores are high, 
or it can be transported across the basolateral membrane to 
reach the plasma (Andrews, 1999). Iron efflux requires two 
proteins: the transporter itself called Ireg1, also known 
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as Metal Transporter 1 (MTP1) or Ferroportin (Abboud and 
Haile, 2000; Andrews, 1999; Donovan et al., 2000; McKie et 
al., 2000), and a multicopper ferroxidase called hephaestin 
(Andrews, 1999; Vulpe et al., 1999). Fe2+ is converted to 
Fe3+ by hephaestin, which is then immediately bound to 
transferrin (Tf). The mechanism of iron loading onto Tf is 
unknown, though it may involve a copper oxidase known as 
ceruloplasmin (Harris et al., 1999). Two molecules of Fe3+ 
can bind to Tf, which renders the iron insoluble under 
physiological conditions, preventing iron-mediated free 
radical toxicity and facilitating transport into cells. 
Most cells in the body are believed to acquire iron from 
plasma Tf via transferrin receptors (TfR) and receptor-
mediated endocytosis (discussed later) (Klausner et al., 
1983). 80% of iron bound to circulating Tf is delivered to 
the bone marrow and incorporated into newly formed 




Figure 1: Schematic Illustration of Iron Absorption 
Iron can be absorbed from the diet into the gut in two different 
forms: either as ferric iron (Fe3+) or as heme. At low pH in the 
gut, most of the free iron is converted to the ferrous (Fe2+) 
form, with some help from the ferrireductase, DcytB. The Fe2+ is 
transported across the apical membrane of the enterocyte via 
DMT1, where it can either be stored in ferritin or be transported 
across the basolateral membrane to reach the plasma. Iron efflux 
is mediated by Ireg1, an iron transporter, and hephaestin, a 
multicopper ferroxidase that converts Fe2+ back to Fe3+, where it 
is bound by Tf.  
Heme is transported across the apical membrane by the recently 
identified heme transporter, HCP1. Within the cell, iron can be 
freed from the protoporphyrin ring by HO1 and join the inorganic 
iron pool, or the heme can transit through the cell intact and be 
exported by the heme transporter Bcrp. 
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 Several factors can regulate iron absorption (reviewed 
in [(Andrews, 1999; Donovan and Andrews, 2004)]): 
1) MUCOSAL BLOCK or DIETARY REGULATOR – Iron absorption 
is affected by recent dietary iron uptake. In the 
event of a large recent iron uptake, the enterocyte 
is rendered refractory to absorption for several 
days.  
2) STORES REGULATOR – Iron absorption is affected by 
levels of total body iron, which is sensed by iron 
saturation in circulating Tf. This iron sufficiency 
information modulates the expression of hepcidin, a 
20-25 amino acid peptide produced in and secreted by 
the liver, which acts as a negative regulator of 
iron absorption (Nicolas et al., 2002; Weinstein et 
al., 2002). Hepcidin levels increase in the presence 
of iron overload, and decreases during iron 
deficiency. This regulation potentially acts at the 
level of the duodenal crypt cells (pre-mature 
enterocytes) and may involve the alteration of 
levels of DMT1 at the apical membrane. 
3) ERYTHROPOIETIC REGULATOR – Iron absorption responds 
to the demands of erythropoiesis, independent of 
total body iron levels. When erythroid cells require 
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iron, hepcidin expression levels decrease and lead 
to increase in iron absorption. The erythropoietic 
regulator has a greater capacity for influencing 
iron absorption than does the stores regulator. 
4) ACUTE HYPOXIA – Iron absorption is stimulated 
through some unknown mechanism. 
Iron can also be absorbed as heme, which can also 
enter the enterocyte via a recently identified heme 
transporter called Heme Carrier Protein 1 (HCP1) (Shayeghi 
et al., 2005), which localizes to the apical membrane of 
duodenal enterocytes. Dietary heme attaches to the brush 
border and is transported into the cells intact. Within the 
cell, iron can be freed from the protoporphyrin ring, 
likely by heme oxygenase 1 (Raffin et al., 1974), an enzyme 
that breaks down heme to liberate iron. This iron can then 
presumable join the inorganic iron pool which can then 
enter the serum via Ireg1, though some heme transits 
through the enterocyte intact and can be exported by two 
heme exporters, Bcrp or FLVCR (Krishnamurthy et al., 2004; 
Quigley et al., 2004).  
Table 1 shows the distribution and usage of iron. It 
is important to note that only 1-3 mg of iron enters the 
body each day, however, the requirement by various 
organelles, such as red blood cells, is much higher. To 
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achieve these high levels, iron is supplied via recycling 
of senescent red cells and catabolism of hemoglobin by 
macrophages. The liver is a primary depot for iron storage 
as hepatocytes can do iron uptake, storage and export, and 
although the major players have not been identified, it is 
believed that ceruloplasmin may play a role in iron export 
through some unknown mechanism (Andrews, 1999; Donovan and 











Table 1: Distribution of iron in the body (adapted from     
(Andrews, 1999)) 
DISTRIBUTION OF IRON
Dietary Iron Uptake 1-2 mg/day
Plasma Transferrin 3 mg
Utilization:
Myoglobin (muscle) 300 mg
Bone Marrow 300 mg
Erythrocytes (hemoglobin) 1800 mg
Storage:
Reticuloendothelial macrophages 600 mg
Liver Parenchyma 1000 mg
Iron Loss 1-2 mg/day
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Part 1.2: Iron Trafficking in the Cell 
 Iron is taken up into the cell via two methods: the 
classical Tf-mediated iron uptake pathway and the Non-
Transferrin Bound Iron (NTBI) uptake. Iron required for 
physiological processes is taken up through Tf-mediated 
iron uptake (Figure 2) (Iacopetta and Morgan, 1983; Karin 
and Mintz, 1981; Klausner et al., 1983). Tf binds to two 
molecules of Fe3+ released from the enterocyte. The Fe-Tf 
then binds to the TfR and, via receptor mediated 
endocytosis, leads to internalization of TfR and DMT1 
within an endocytic vesicle containing holo-Tf. 
Acidification of the endosome to pH 5.5 – 6.0 via an ATP-
dependent proton pump leading Tf to release iron and bind 
tighter to TfR (Dautry-Varsat et al., 1983; Paterson et 
al., 1984; Van et al., 1982; Yamashiro et al., 1984). Iron 
then exits the endosome via DMT1 and enters the 
intracellular labile iron pool, which is then delivered to 
the mitochondria for heme biosythesis and formation of 
iron-sulfur clusters or to ferritin for storage. The iron 
is so tightly regulated in the cell by binding to protein 
that the labile iron pool cannot be measured. The intact 
apoTf-TfR complex recycles to the cell surface, where the 
neutral pH promotes the detachment of Tf from TfR and back 







Figure 2: The Transferrin Cycle 
 
Iron required for physiological processes is taken up 
through the transferrin (Tf) cycle. Tf binds to two 
molecules of Fe3+ released from the enterocyte, which then 
binds to the Tf receptor (TfR) and, via receptor mediated 
endocytosis, leads to the internalization of TfR and DMT1 
within an endosome. Acidification of the endosome to pH 5.5 
allows Tf to release the iron, which then exits the 
endosome via DMT1 into the labile iron pool. The intact Tf-
TfR complex then recycles to the cell surface, where the 
neutral pH promotes the detachment of Tf from TfR and back 
into circulation. 
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For NTBI uptake, DMT1 in the plasma membrane directly 
mediates iron transport, though this iron is not used for 
physiological purposes(Fleming et al., 1997; Gunshin et 
al., 1997). It’s been postulated that this iron may act in 
a pathophysiological manner. NTBI uptake can occur when 
iron overload produces fully saturated Tf. This NTB iron 
circulating is in a chelatable, low molecular weight form 
and is weakly associated with albumin, citrate, amino acids 
and sugars (Farcich and Morgan, 1992; Fleming et al., 1997; 
Garrick et al., 1999; Richardson and Ponka, 1997). Non-
hematopoietic tissues, such as the liver, endocrine organs, 
kidneys and heart, can preferentially take up this iron. In 
the brain, the free iron levels exceed that of Tf, so NTBI 
uptake is also used (Moos and Morgan, 1998; Rouault, 2001). 
 
 Transferrin 
 Plasma Tf is a 80 kDa glycoprotein synthesized in and 
secreted by the liver. It contains N-terminal and C-
terminal iron binding domains (reviewed in [(Huebers et 
al., 1984)]). These domains are globular structures of 330 
amino acids divided into subunits with iron binding and 
anion binding sites in the intersubdomain cleft. This cleft 
opens with release of iron and closes with binding 
(reviewed in [(Baker and Lindley, 1992)]). Tf has six 
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coordination sites for binding to iron, with a Kd of 10-22 
M, and only in the presence of an anion, predominantly 
carbonate. The anion serves as a bridge between metal and 
protein, excluding water from two coordination sites (Aisen 
and Listowsky, 1980; Shongwe et al., 1992).  The remaining 
four coordination sites on Tf consist of a histidine 
nitrogen, an aspartate carboxyl oxygen and two tyrosine 
phenolate oxygen (Anderson et al., 1989; Bailey et al., 
1988). Anion binding must take place before iron binding; 
iron release from Tf involves protonation of the carbonate, 
during the acidification of the endosome, thus loosening 
the metal-protein bond. Each molecule of Tf can bind to two 
molecules of diferric iron. The average Tf molecule has a 
half-life of eight days and may be used up to 100 times for 
iron delivery (Harford et al., 1994). Tf is not universally 
required for efficient iron transport, but it is the major 
physiological source for iron in the body. 
 
Transferrin Receptor 
 The TfR is a single transmembrane, disulfide-linked 
homodimer of two glycoproteins of 760 amino acids each 
(Cheng et al., 2004b). Each monomer has four glycosylation 
sites, three are N-linked while one is O-linked, leading to 
a 90 kDa protein (Hayes et al., 1992). Mutations that 
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abolish N-linked glycosylation lead to the receptor having 
decreased Tf-binding and surface expression (Williams and 
Enns, 1991; Williams and Enns, 1993). The transmembrane 
domain resides between amino acids 62-89 and functions as 
an internal signal peptide (Zerial et al., 1986).  TfR has 
the ability to bind to both monoferric (Kd = 10-6/mole) and 
diferric (Kd = 10-7 – 10-9M) iron (Sawyer and Krantz, 1986; 
Stein and Sussman, 1986); as the concentration of 
circulating Tf is 25µM, the TfRs are normally fully 
saturated. Binding of Tf to Tfr is mediated by its C-
terminus (Zak et al., 1994); once bound, the Tf-TfR complex 
is rapidly internalized into clathrin-coated pits to form 
endocytic vesicles. This process requires the 61 amino acid 
intracellular tail of TfR (Girones et al., 1991; McGraw and 
Maxfield, 1990; Rothenberger et al., 1987), specifically 
the conserved Tyr-Thr-Arf-Phe (YTRF) sequence which 
functions as a signal for endocytic internalization 
(Collawn et al., 1993).  
 The expression level of TfR is regulated by the 
intracellular levels of iron. At low iron levels, the 
expression is increased to bring more iron into the cell, 
while conversely, at high iron levels, the expression level 
of TfR is decreased. This regulation is mediated by Iron 
Regulatory Proteins (IRPs) binding to Iron Response 
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Elements (IREs) on the mRNA of TfR (details discussed 
below) (reviewed in [(Hentze et al., 2004)]). 
 
Ferritin 
 Ferritin is the cellular iron storage protein (Torti 
and Torti, 2002). A complex 24 subunit heteropolymer made 
up of heavy (H) and L (light) chains. The H-chains are 21 
kDa while the L-chains are 19.7 kDa. These form a sphere 
with a hollow interior that is capable of binding up to 
4500 atoms of crystalline iron (Harrison, 1977; Theil, 
1987) in a soluble, non-toxic but bioavailable form, such 
as ferrihydrite. The H-chain has ferroxidase activity, able 
to convert Fe2+ to Fe3+, promoting incorporation into 
ferritin (Lawson et al., 1991; Levi et al., 1988). The L-
chain is associated with nucleation of the mineral core 
within the protein shell. Different combinations of each of 
the subunits lead to different isoforms of ferritin, which 
show tissue specific variation (Drysdale, 1988). Ferritins 
that are heavy in L-chains correlate to increased iron 
storage while ferritins that are predominantly H-chains 
correlate with increased iron utilization and response to 
stress (Drysdale, 1988; Theil, 1987). The H:L ratio 
increases with activation of heme synthesis or cellular 
proliferation (McClarty et al., 1990; Pattanapanyasat et 
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al., 1987). Over time, ferritin molecules aggregate to form 
clusters with are engulfed by lysosomes and degraded 
(Bridges, 1987), resulting in an end product known as 
hemosiderin. In the case of iron overload, there is an 
increase in hemosiderin that can be visualized by Prussian 
blue staining.  
 The expression level of ferritin is regulated in a 
pattern opposite that of TfR. At low iron levels, the 
expression is decreased so that storage is minimized and 
more iron can be brought into the cell, while at high iron 
levels, the expression level is increased. The expression 
is regulated by the same IRP/IRE system as that which 
regulates TfR (reviewed in [(Hentze et al., 2004)]). 
 
Divalent Metal Transporter (DMT1) 
 DMT1 is a ubiquitously expressed twelve trans-membrane 
channel localized to the plasma membrane and is the only 
known mammalian iron importer in the cell. Originally 
identified as Natural Resistance Associated Macrophage 
Protein-2 (NRAMP2) and Divalent Cation Transporter (DCT1) 
(Cellier et al., 1995; Fleming et al., 1997; Gunshin et 
al., 1997), it channels iron preferentially in the ferrous 
form, but can also channel cobalt, manganese, copper, 
cadmium, lead and zinc, but not calcium or magnesium. There 
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are two different splice forms of DMT1, encoding different 
C-termini and different 3’ untranslated regions (UTRs). In 
one form, the 3’UTR can contain an IRE, though whether DMT1 
expression is regulated by IRPs is still unknown (Gunshin 
et al., 2001; Hubert and Hentze, 2002).  Different DMT1 
isoforms are present in different tissues: the +IRE form is 
found in enterocytes, while in the brain, the –IRE form is 
dominant. 
 DMT1 is known to transport iron across the apical 
membrane of the enterocyte and also to transport iron out 
of the endosome after Tf-TfR mediated iron uptake. The 
function of DMT1 is pH dependent, working optimally at low 
pH and has been reported to co-transport protons. Rodents 
that have a naturally occurring mutation in DMT1, known as 
microcytic anemia (mk) mice or Belgrade (b) rats, where 
glycine 185 is mutated to arginine (G185R) have defects in 
iron import and are anemic (Fleming et al., 1997; Fleming 
et al., 1998). In this case, DMT1 can no longer channel 




 IRPs and IREs are involved in the post-transcriptional 
control of the expression of many molecules involved in 
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iron homeostasis: TfR, ferritin, DMT1, Ireg1, etc. 
(reviewed in [(Eisenstein, 2000)]) and act as the sensor 
for the intracellar levels of iron. IREs are short 
untranslated 30 nucleotide sequences that form stable stem 
loop structures which are docking sites for IRPs (Andrews, 
2000). There are two IRPs: IRP1 and IRP2, which are 
cytoplasmic proteins that bind to IREs in 5’ or 3’UTRs of 
mRNAs (Hentze and Kuhn, 1996).  IRP1 is functions normally 
as an aconitase, however, in the presence of low iron 
levels, it switches and binds to IREs in TfR and ferritin 
mRNAs. This switch in activity is dictated by the iron-
sulfur clusters within IRP1, which is how it senses iron 
levels. At normal iron levels, the iron-sulfur clusters are 
intact and IRP1 acts as an aconitase. At low levels, the 
iron-sulfur clusters can no longer form, and IRP1 binds to 
IREs. IRP1 is modulated by nitric oxide, as well as oxygen 
– during hypoxia, IRP1 binding to IREs is decreased (Haile 
et al., 1992; Kaptain et al., 1991). 
IRP2’s regulation is different from that of IRP1. IRP2 
binds to IREs in low iron conditions and is degraded at 
high iron concentrations. This is dependent on a cysteine-
rich 73 amino acid sequence that is unique to IRP2, which 
leads to an iron dependent oxidation event. Under high iron 
conditions, this oxidized form is a target for 
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ubiquitination and proteosomal degradation (Kang et al., 
2003; Yamanaka et al., 2003). In the brain, there is more 
IRP2 than IRP1, which is reversed in the heart and liver, 
and IRP2 knockout mice have iron overload in the central 
nervous system (CNS) and neurodegenerative disease (LaVaute 
et al., 2001; Rouault, 2001). 
In the case of TfR, IRP1 binds to multiple IREs at the 
3’UTR, thus stabilizing the message and allowing 
translation of TfR to bring more iron into the cell (Hentze 
and Kuhn, 1996). In the case of ferritin, IRP1 binds to the 
5’UTR and blocks translation, thus decreasing the levels of 
the storage protein (Gray and Hentze, 1994).For DMT1, the 
IRPs bind to the 3’ IRE while for Ireg1, the IRPs bind to 
the 5’ IRE, but it is unknown if this really contributes to 
their regulation (Gunshin et al., 2001).  
 
Other proteins involved in iron homeostasis 
 Table 2 shows a brief overview of other proteins 
involved in iron homeostasis. All of these proteins work 
together to tightly regulate the entry of iron into cell, 
starting with dietary iron entry in the gut to iron uptake 
in individual cells. Mutations in many of these proteins 
leads to either iron overload or iron deficiency. 
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PROTEIN Function Disease Iron Status
Transferrin Ferric iron transporter Hypotransferrinemia Severe hypochromic,   




HFE unknown function, Hereditary Iron overload
but binds to TfR in Hemochromatosis
enterocytes
Ferritin Iron Storage in the Cell Neuroferritinopathy Iron overload
IRP1 Iron sensor, binds to IREs
IRP2 Iron sensor, binds to IREs IRP2 -/- mice Iron overload in  
CNS and
neurodegeneration
DMT1 Iron transporter mk mice Iron deficiency





Ireg1 Iron export from 
the enterocyte
Ceruloplasmin Copper ferroxidase Aceruloplasnemia Iron overload in 
the brain but decrease
in serum iron
Hephaestin Copper ferroxidase
at basal membrane 
Frataxin Regulation of iron Friedrich's ataxia Iron overload
export from
the mitochondria
Huntingtin Trafficking of TfR Huntington's Disease Iron overload
Heme Oxygenase 1 Breakdown of heme 
to release iron
Pantothenate Regulation of Halloverden-Spatz Iron overload





Table 2: A brief overview of proteins involved in iron 
homeostasis, and where known, diseases associated with 
mutations in the gene and the iron disposition in the 
cell/body. 
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Part 1.3: Iron homeostasis in the brain 
 Iron homeostasis in the brain is similar to that of 
the rest of the body in that all of the major proteins 
associated with regulating iron in the systemic circulation 
are also expressed in the central nervous system (CNS). 
However, iron acquisition by the CNS is problematic as the 
CNS is functionally separate from the systemic circulation 
by the blood-brain barrier and the blood-cerebrospinal 
barrier, and thus, cannot acquire iron from circulating 
serum Tf (reviewed in [(Rouault, 2001)]). Nutrients must be 
taken up by the barrier cells and specifically exported 
into the distal compartment.  Little is known about the 
mechanism of iron release into the brain or the regulation 
of transport mechanisms. It is postulated that cells in the 
brain must send a signal that iron is required to the 
endothelial cells lining the blood vessels in the brain and 
that these cells release iron into the brain extracellular 
fluid (Burdo and Connor, 2003).  
 Iron is abundant in the brain and has distinct 
regional and cellular pattern of distribution, highest in 
the basal ganglia at a concentration equivalent to that of 
the liver (Thomas and Jankovic, 2004). Within the basal 
ganglia, iron is highest in the globus pallidus, followed 
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by the zona reticulata of the substantia nigra, the red 
nucleus and the putamen (Sorond and Ratan, 2000). Iron is 
predominantly stored in the oligodendrocytes, cells that 
produce and maintain myelin (Sorond and Ratan, 2000). They 
regulate iron availability to neurons and are found 
associated with blood vessels where they monitor transport 
of iron across the BBB. The oligodendrocytes are also a 
source for brain Tf, as is the choroid plexus and 
epithelial cells, but the amount of Tf made is about 100-
fold lower than that of serum Tf (Burdo and Connor, 2003; 
Sorond and Ratan, 2000). In fact, unlike the systemic 
circulation, iron is often found to be as much as a molar 
excess relative to that of Tf iron binding capacity and 
thus, brain Tf is often saturated. Under normal conditions, 
there may be significant NTBI uptake into cells. This NTB 
iron may be associated with low molecular weight molecules, 
such as citrate and ascorbate, which aid in its transport 
around the brain (Burdo and Connor, 2003; Rouault, 2001).   
 Similar to systemic iron homeostasis, the following 
proteins are involved, with some proteins being found 
specifically in the brain (reviewed in [(Thomas and 
Jankovic, 2004)]): 
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1) UPTAKE - Tf/TfR, melanotransferrin, 
lactotransferrin, DMT1, MTP1/Ireg1 and Stimulator of 
Iron Transport (SFT) 
2) STORAGE – Ferritin, neuromelanin 
3) RELEASE – Ceruloplasmin/ferroxidase, HO1 
4) METABOLISM – HO1, Tf, ferroreductase 
5) POST-TRANSCRIPTIONAL CONTROL: IRP1, IRP2, IREs, 
DMT1, changes in redox state of the cell 
 
Part 1.4: Iron and Neurodegeneration 
 Most of the studies of iron in the brain have centered 
around its pathophysiological properties and participation 
in various neurodegenerative diseases (reviewed in [(Ponka, 
2004; Rouault, 2001; Shoham and Youdim, 2000; Zecca et al., 
2004)]). Iron accumulates normally as a result of ageing, 
however, when iron is present in excess, it has the ability 
to produce reactive oxygen species, such as hydroxyl 
radicals, via Fenton Chemistry, which can augment neuronal 
injury (Gutteridge et al., 1981).  These hydroxyl radicals 
are highly reactive and can attack proteins, lipids and 





Fenton Reaction: Fe2+ + H2O2  →  OH• + OH- + Fe3+ 
 There are two classes of iron related 
neurodegenerative disorders: 1) those that result from 
defects in iron metabolism and/or homeostasis and present 
with neurological defects, such as aceruloplasminemia and 
Friedrich’s ataxia and 2) those neurological diseases that 
present with iron accumulation in specific brain regions, 
such as Huntington’s disease and Alzheimer’s disease. For 
example, in Parkinson’s disease, there is an increased iron 
content in neuromelanin-containing cells, particularly in 
the substantia nigra (Zecca et al., 2004). In both cases, 
this involves protein modification, misfolding and 
aggregation, and formation of intracellular inclusion 
bodies, all of which are hallmarks of many 
neurodegenerative diseases. In the second class of 
neurodegenerative diseases, it is unknown whether the iron 
accumulation seen is just a by-product of degenerating 
neurons or whether the high iron concentration contributes 
to the pathology of the disease.  
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PART 2: DEXRAS1 AND RHES 
Part 2.1: Dexras1  
 Dexras1 is a small G-protein belonging to a subfamily 
of Ras proteins.  It was originally revealed by 
differential display as an upregulated mRNA after treatment 
with dexamethasone, a synthetic glucocorticoid (Kemppainen 
and Behrend, 1998). Dexras1's mRNA was shown to be 
upregulated in as little as 30 minutes, peaking at 2 hours. 
Northern blotting results have shown that Dexras1 is 
enriched in the brain, but is also localized to the heart, 
liver and kidneys. The cDNA encoding the protein was found 
to be about 900 bases or about 30 kDa. While Dexras1 
contains all of the conserved G-protein regions, such as 
the P-loop at the N-terminus, which binds to GDP/GTP, the 
magnesium binding loop and a C-terminal CAAX box, a 
prenylation site, it differs from the typical small GTPases 
as it has an extended C-terminal tail of about 7 kDa 
(Kemppainen and Behrend, 1998). Like all G-proteins, 
Dexras1 is inactive when bound to GDP. Upon binding to GTP, 
it undergoes a confirmational switch, at which point it can 
bind to downstream effector molecules. The functions for 
Dexras1 have been fairly diverse; so far it has been found 
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to inhibit cyclic AMP-dependent ACTH secretion (Graham et 
al., 2001; Kemppainen and Behrend, 1998), bind to and act 
as a guanine nucleotide exchange factor (GEF) for the 
heterotrimeric G-protein (Gαi2) leading to inhibition of 
adenylate cylase (Cismowski et al., 2001; Cismowski et al., 
2000; Graham et al., 2002; Graham et al., 2004; Kemppainen 
and Behrend, 1998), and is localized to the suprachiasmatic 
nucleus where it is involved in the entrainment of the 
circadian clock (Cheng et al., 2004a; Takahashi et al., 
2003).  
 In order for a G-protein to be activated, it must 
release GDP and bind to GTP. This is the rate-limiting step 
in the activation of G-proteins, thus, these small G-
proteins usually require some kind of GEF to catalyze the 
exchange of GDP for GTP. Thus far, no protein GEF has yet 
been identified for Dexras1. 
Nitric oxide (NO) is a well-established 
neurotransmitter in the brain and in the nerves of the 
autonomic nervous system throughout the body. Its primary 
functions are muscle relaxation, penile erection and 
movement of food through the digestive tract (Furchgott and 
Zawadzki, 1980; Ignarro et al., 1987; Palmer et al., 1987).  
NO is a produced by nitric oxide sythase (nNOS) (Bredt and 
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Snyder, 1990), which converts arginine to citrulline, 














There are several forms of NOS. Neuronal NOS (nNOS) 
has a molecular weight of 160 kDa, while endothelial NOS 
(eNOS) and macrophage NOS (mNOS or iNOS) are about 130 kDa. 
nNOS and eNOS are constitutively expressed, while iNOS is 
inducible (Hibbs, Jr. et al., 1987; Stuehr and Nathan, 
1989). All isoforms occur as dimmers. 
nNOS is stimulated to produce NO via the NMDA 
receptor. Glutamate binds to the NMDA receptor, causing 
calcium channels to open, such that the intracellular 
calcium concentration is increased.  The calcium binds to 
calmodulin, which binds and activates NOS, in turn, leading 
to NO production and diffusion of NO from the neuron.  NO 
release from the neuron leads to activation of guanyl 
cyclase, leading to the production of cGMP as a secondary 
messenger (Bredt et al., 1990; Bredt and Snyder, 1989).   
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 A second role for NO is protein S-nitrosylation (Hess 
et al., 2005). The nitric oxide moiety is usually attached 
at a cysteine residue side chain. Because NO is highly 
reactive and is easily inactivated by oxygen, superoxide 
and glutathione, it is increasingly appreciated that NO may 
not simply diffuse freely to reach its physiological target 
but may be conveyed to these sites by interactions of nNOS 
with other proteins. We have previously identified CAPON, a 
55 kDa protein that contains a C-terminal domain that binds 
to the PDZ domain of nNOS as well as an N-terminal 
phosphotyrosine binding (PTB) domain (Jaffrey et al., 
1998). CAPON interacts with Dexras1, creating a tertiary 
complex between nNOS, CAPON and Dexras1 (Fang et al., 
2000). This leads to the nitrosylation of Dexras1 on 
cysteine-11, thus activating Dexras1, by causing the 
protein to bind to GTP in the absence of a protein GEF 
(Figure 3) ((Fang et al., 2000; Jaffrey et al., 2002). The 
selective lessening of Dexras1 activation in the brains of 
mice with targeted deletion of nNOS and the existence of a 
ternary complex of nNOS, CAPON and Dexras1, establish that 
neuronally derived NO physiologically serves as a guanine 
nucleotide exchange factor to activate Dexras1 by S-




Figure 3: Dexras1 is regulated by NMDA and nNOS 
 
Glutamate-NMDA binds to the NMDA receptor at the plasma 
membrane, allowing calcium (Ca2+) to flux through the 
receptor and enter the cytoplasm, where it binds to 
calmodulin. This Ca2+-calmodulin complex activates nNOS to 
produce nitric oxide (NO). nNOS interacts with Dexras1 via 
the adaptor protein CAPON, leading to S-nitrosylation and 
activation of Dexras1.
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Part 2.2: Rhes 
 
 Rhes (Ras homolog enriched in striatum) is the closest 
homolog to Dexras1, sharing 62% identity (Figure 4). Though 
it shares homology with Dexras1, it is not 
transcriptionally regulated by dexamethasone, but rather, 
thyroid hormone (Falk et al., 1999; Vargiu et al., 2001). 
Rhes contains all of the conserved domains of the classical 
GTPases, but like Dexras1, it also contains that extended 
C-terminal tail of unknown function. Due to its selective 
expression in the striatum, it has been shown to be 
involved in striatal function, where Rhes knockout mice had 
impaired locomotor function and increase in anxiety (Spano 
et al., 2004). Rhes has also been shown to regulate signal 
transduction from G-protein coupled receptors. Rhes is 
post-translationally farnesylated and targeted to the 
membrane. Rhes is able to bind to and activate 
phosphoinositide 3-kinase (PI3K). Rhes also interferes with 
the cyclic AMP (cAMP)/ Protein Kinase A (PKA) pathway 
mediated by the thyroid stimulating hormone (TSH) receptor 
(Vargiu et al., 2004).  
 Though Rhes and Dexras1 are highly homologous, no 
study has yet been performed to determine whether Rhes is 










Figure 4: Sequence alignment of Dexras1 and Rhes 
 
Dexras1 and Rhes share 68% homology at the amino acid 
level, with the typical conserved regions found in all GTP 
binding proteins sharing the highest homology. Rhes also 
contains the extended 7kDa C-terminal tail that Dexras1 
has, but that is absent in other small G-proteins.
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CHAPTER 2: 
Materials and Methods 
 
Cells and Reagents 
HEK 293T cells were maintained in DMEM with 10% fetal 
bovine serum (FBS), 2 mM L-Glutamine and 100U/ml 
penicillin-streptomycin (PS) at 37°C with 5% CO2 atmosphere 
in a humidified incubator. PC12 cells were maintained in 
DMEM with 10% FBS, 5% horse serum, 2 mM L-glutamine and 
100U/ml PS in the same environment. All chemicals were 
purchased from Sigma, unless otherwise indicated. 
 
Generation of constructs 
Rat PAP7 was cloned from EST #5621578 (Open Biosystems) 
into either pCMV-GST or pCMV-HA (Clontech). Rat Dexras1, 
wild-type and A178V or C11S mutants, were all cloned into 
pCMV-Myc (Clontech).  
 
Characterization of PAP7 
To examine the expression pattern of PAP7 throughout the 
body, a male C57/B6 mouse was dissected and each organ was 
homogenized in Buffer A (100 mM Tris pH 7.4, 150 mM NaCl, 
1% Triton X-100, 15% Glycerol, 1 mM PMSF, 25 µg/ml antipain, 
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50 µg/ml leupeptin, 50 µg/ml aprotinin, 25 µg/ml chymostatin 
and 25 µg/ml pepstatin). Total protein (100 µg) was loaded 
onto a Western blot and immunoblotted with a rabbit anti-
nNOS antibody (previously generated in our laboratory), 
rabbit anti-PAP7 (V. Papadopolous) antibody and rabbit 
anti-Dexras1 antibody (Calbiochem).  
To examine the expression pattern of PAP7 in the brain, a 
male Sprague-Dawley rat brain was dissected into several 
parts, lysed in Buffer A, and total protein (100 µg) loaded 
and a Western blot performed.  
To examine the expression pattern of PAP7 and Dexras1 in 
different cell lines, 100 µg of total protein from each cell 
line lysed in Buffer A was loaded onto a Western blot. 
 
GST pull-down assay 
GST or GST-tagged PAP7 constructs were co-transfected with 
Dexras1-Myc constructs into HEK 293T cells using PolyFect 
(Qiagen), with a transfection efficiency of greater than 
90%. Cells were lysed 48h after transfection in Buffer A. 
Lysates were pre-cleared with pansorbin cells (Calbiochem), 
then 1 mg of total protein was incubated with glutathione-
Sepharose beads overnight at 4°C. Beads were washed with 
Wash Buffer A (50 mM Tris pH 7.4, 500 mM NaCl, 10 mM β-
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glycerophosphate) twice, then once with Buffer A. Beads 
were quenched in sample buffer (100 mM Tris, pH 6.8, 10% 
glycerol, 250 mM β-mercaptoethanol, 2% sodium dodecyl 
sulfate and bromophenol blue). Total protein (50 µg) was 
loaded as input. Dexras1-Myc binding was examined using an 
anti-myc antibody (Roche) followed by incubation with anti-
mouse secondary conjugated to horseradish peroxidase(HRP) 
(Jackson Immunoresearch); blots were then stripped and 
probed with an anti-GST antibody conjugated to HRP to 
detect PAP7. Chemiluminescence (Pierce) was used to detect 
bands on the Western blot. 
 
Co-immunoprecipitation 
Undifferentiated PC12 cells were lysed in Buffer A and 
lysates were pre-cleared with protein A Sepharose. 1 mg of 
total protein was incubated with 2 µg of either goat anti-
Dexras1 antibody (Abcam) or rabbit anti-NRAMP2 antibody 
(Alpha Diagnostics) overnight at 4°C, then protein A 
Sepharose beads were added for 1h. Beads were washed in 
Buffer A three times and quenched in sample buffer. Total 
PC12 lysate (100 µg) was loaded as input. PAP7 binding was 
detected using a rabbit anti-PAP7 antibody, followed by 
anti-rabbit Ig conjugated to HRP. 
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For the ternary complex interaction, a male C57/B6 mouse 
was sacrificed and the whole brain was dissected and 
homogenized in Buffer A. Lysates were pre-cleared with 
protein A Sepharose. 1 mg of total protein was incubated 
with 2 µg of rabbit anti-PAP7 antibody overnight at 4°C, 
then protein A Sepharose beads were added for 1h. Beads 
were washed in Buffer A three times and quenched in sample 
buffer. Total brain lysate (100 µg) was loaded as input. 
Dexras1 and DMT1 binding was detected using a rabbit anti-
Dexras1 or anti-NRAMP2 antibody, followed by anti-rabbit Ig 
conjugated to HRP. 
 
Immunofluorescence Staining 
Undifferentiated PC12 cells were plated on poly-D-lysine 
coated glass coverslip dishes. For PAP7 localization to the 
Golgi, these cells were transfected with a plasmid 
containing a Golgi marker conjugated to YFP (pEYFP-Golgi, 
Clonetech) using Lipofectamine 2000 (Invitrogen). After 48 
hours, cells were stained as below. 
Cells were fixed in 4% paraformaldehyde in PBS, 
permeabilized in 1% Triton X-100 in PBS and blocked in PBS 
with 1% normal goat serum and 2% normal horse serum. 
Endogenous Dexras1 was detected using a goat anti-Dexras1 
antibody; endogenous PAP7 was detected using a rabbit anti-
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PAP7 antibody. Anti-goat Ig conjugated to FITC and anti-
rabbit Ig conjugated to rhodamine was obtained from 
Molecular Probes. Confocal microscropy images were obtained 
using a PerkinElmer UltraView LCI (Live Cell Imaging) 
System. 
 
S-nitrosylation of Dexras1 
PC12 cells were treated with various concentrations of GSNO 
(Alexis Biochemicals) for 3h. Cells were washed in PBS and 
harvested. S-nitrosylation of Dexras1 was monitored using 
the biotin-switch assay previously described (Jaffrey and 
Snyder, 2001). Dexras1 was detected on the immunoblot using 
a rabbit anti-Dexras1 antibody (Calbiochem).  
 
Iron Uptake Assays 
In HEK 293T Cells - NTBI uptake assays were performed as 
previously described (Picard et al., 2000). In brief, HEK 
293T cells were transfected (greater than 90% efficiency) 
with PAP7-HA and Dexras1-Myc (or mutants) using 
Lipofectamine and PLUS Reagent (Invitrogen) for 3h in DMEM 
only, then supplemented with full media After 48h, the 
cells were washed with phosphate buffered saline (PBS) then 
resuspended into Iron Uptake Buffer (25 mM Tris, 25 mM MES, 
140 mM NaCl, 5.4 mM KCl, 5 mM glucose, 1.8 mM CaCl2, pH 5.5) 
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and transferred to glass test tubes. Ascorbic acid was 
added to 1 mM FeSO4 at a 44:1 ratio. 55FeCl3 (PerkinElmer 
Life Science) was added to the iron/ascorbic acid mixture, 
which was then added to the cells in Iron Uptake Buffer to 
a final concentration of 20 µM. Cells were incubated at 37°C 
with shaking for 30 minutes. The cells were washed twice 
with cold PBS + 0.5 mM EDTA and harvested. An aliquot of 
resuspended cells was taken for protein assay using the 
Bio-Rad Protein Assay Reagent; the protein concentrations 
of individual samples were used to quantitate 55Fe 
incorporation (cpm/µg protein). Samples were normalized to 
control. 
In primary cortical neurons - Cells were dissected out of 
E16-E18 wild-type or nNOS knockout mice and plated in 6 
well plates at 3 X 106 cells per well. Cells were maintained 
in Primary Neuron Media (Neurobasal media supplemented with 
B27 serum, 2 mM L-glutamine and 100U/ml PS) at 37°C with 5% 
CO2 atmosphere in a humidified incubator. Using this media, 
the growth of the glia is suppressed and the amount of glia 
is less than 0.5% of the total culture, giving us an 
essentially pure neuronal culture. 
Neurons were aged 14-20 days after plating before being 
used for iron uptake assays. Cells were treated as follows: 
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100µM NMDA for 30 min, 300µM NMDA for 10 minutes or 5 µM 
ionomycin for 10 min. For samples with MK801, cells were 
pre-treated with 10 µM MK801 for 10 min, then 100 µM NMDA 
was added for 30 min. Cells were then washed once with warm 
PBS. For samples with MK801, the drug was added back after 
NMDA treatment.  
For NTBI uptake assays, 1 ml of warm Iron Uptake Buffer 
containing 20 µM iron prepared as above was added to each 
well and incubated at 37°C with 5% CO2 atmosphere in a 
humidified incubator for 30 min. Cells were harvested, 
washed twice in cold PBS + 0.5 mM EDTA and processed as 
above. 
For Tf-iron uptake pathway, assays were performed as 
previously described (Kim and Ponka, 2002). In brief, apo-
transferrin was loaded with 55Fe2+ and the concentration 
measured. After treatment, cells were incubated in a final 
concentration of 10 µM transferrin (1 µM 55Fe-transferrin 
and 9 µM holo-transferrin) in 1 ml of Primary Neuron Media 
for 2h. Cells were harvested, washed twice in cold PBS + 
0.5 mM EDTA and processed as above. 
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RNA Interference in PC12 cells 
The Dexras1 RNA interference (RNAi) insert was designed 
using the Genescript siRNA design center and cloned into 
pRNAT-U6.1/Neo (Genescript). To obtain knockdown in PC12 
cells, 24 µg of Dexras1 RNAi were transfected into cells 
using Lipofectamine 2000 (Invitrogen) in Optimem overnight. 
Control transfection used the pRNAT-U6.1/Neo empty vector. 
The next morning, cells were fed with full media and 
allowed to recover for 24h. They were transfected again 
overnight, and then allowed to recover for 2 days before 
treatment with GSNO for 3h. The transfection efficiency 
after the double transfection was greater than 90%. To 
monitor knockdown, lysate (100 µg) was run on a Western blot 
(mock transfected cells had no DNA), and Dexras1 protein 
levels were monitored using a rabbit anti-Dexras1 antibody.  
 
Heme Incorporation Assay 
Primary rat cortical neurons were treated with 100 µM NMDA, 
then incubated in 55Fe-transferrin as described above. Cells 
were washed in PBS + 0.5 mM EDTA, then resuspended in 1 ml 
of 0.2N HCl. Using an aliquot of cell lysate, the protein 
concentration of individual samples was determined using 
the Biorad Protein Assay. The resuspended cells were heated 
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at 100°C for 10 minutes, cooled on ice, and then transferred 
to glass test tubes. 10% TCA (3 ml) was added to each 
sample, vortexed, and incubated on ice for 15 minutes. 
Protein precipitate was pelleted by centrifugation, and the 
pellet was washed in 3 ml of 10% TCA, and resuspended in 
500 µL of 0.2N HCl. Scintillation fluid was added and 55Fe2+ 
incorporated into heme counted in a scintillation counter. 
Samples were normalized to control. 
 
HemoQuant Assay 
To measure heme content in whole brains, the HemoQuant 
assay was performed as previously described (Schwartz et 
al., 1983). Whole brains from age-matched wild-type and 
nNOS knockout mice were lysed in 4 ml of Buffer A. 50 µg of 
lysate was added to 1 ml of saturated 2M oxalic acid in a 
glass test-tube. Two sets of triplicates were set up for 
each sample – one set are blanks, while the other set are 
samples. The sample set was boiled at 100°C for 30 minutes, 
then cooled to room temperature. The blank set was left at 
room temperature. Boiling samples in 2M oxalic acid 
converts heme to prophyrin, the fluorescence of which was 
read in a spectrofluorometer using 400 nm excitation and 
662 nm emission. The blank values were subtracted from the 
 39
sample values. nNOS knockout porphyrin readings were 
normalized to the age matched wild-type controls (100%).  
 
Measurement of Reactive Oxygen Species 
To measure highly reactive oxygen species (hROS), such as 
hydroxyl free radicals generated by the Fenton reaction, we 
employed 2-[6-(4'-hydroxy)phenoxy-3H-xanthen-3-on-9-
yl]benzoic acid (HPF) (Cell Technology, Inc, Mountain View, 
CA) (Setsukinai et al., 2003). This scarcely fluorescent 
compound binds specifically to hydroxyl free radicals, and 
less specifically to peroxynitrate, and converts to a 
highly fluorescent molecule.  
Rat primary cortical neurons were prepared as above and 
aged for 14 days after plating. Measurement of hROS was 
conducted according to the manufacturer’s protocol. 
Briefly, neurons were pretreated with either 0 µM or 100 µM 
SIH for 3 hours in full media, which was then removed, and 
the cells were washed once with Hanks Balanced Salt 
Solution (HBSS). 5 µM HPF in HBSS was added to the cells and 
incubated at 37°C with 5% CO2 atmosphere in a humidified 
incubator for 30 min. 0 µM or 300 µM NMDA was then added to 
the cells and incubated for another 30 minutes. Cells were 
harvested in HBSS and fluorescence was measured in a 
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fluorimeter utilizing excitation 488 nm and emission 515 
nm.  
Phosphorylation Studies 
To examine in vivo phosphorylation of PAP7, we transfected 
HEK 293T cells with a myc-tagged construct using Polyfect. 
48 hours after transfections, we replaced the media on the 
cells with DMEM (Invitrogen) containing no sodium phosphate 
and supplemented with 32P-orthophosphate (Perkin Elmer) and 
incubated for 4 hours. All inhibitors were made up in DMSO 
and added at this time at the following final 
concentrations: 1 µM staurosporine, 1 µM H-89, 1 µM GFX, 25 
µM TBB, 50 µM DRB, 100 µM Olomoucine, 10 µM SB-216763 and 1 
µM Indirubin-3-monoxime (Biomol). Cells were rinsed twice in 
PBS and lysed in Buffer A. Cell lysates were precleared 
using Pansorbin cells for 30 minutes and a protein assay 
performed. Immunoprecipitations were performed using 1 mg 
of total lysate and 2 µg of anti-myc antibody, pulled down 
with Protein A Sepharose. Beads were washed with Buffer A 
three times, quenched in sample buffer and loaded on a 4-
12% Bis-Tris gel. The gel was then either stained with 
Commassie stain or transferred to nitrocellulose. After 
autoradiography, blots were probed with anti-myc antibody 
for sample input. 
 41
To examine in vitro phosphorylation of PAP7, Dexras1 and 
Rhes, we transfected HEK 293T cells with myc-tagged 
constructs using Polyfect. After 48 hours, cells were 
harvested and immunoprecipitations were performed as above 
using an anti-myc antibody. After washing the samples twice 
in Wash Buffer A, once in Buffer A and then twice in PBS, 
samples were either untreated or treated with lambda-
phosphatase at 30C for 2 – 4 hours, then washed again three 
times with PBS. The samples were then treated with 
different kinases and 32P-gamma-ATP (Perkin Elmer) for 30 
minutes at 30C. The samples were quenched in SDS-PAGE 
buffer, loaded on a 4-12% Bis-Tris gel and transferred to 
nitrocellulose. The blot was exposed to film, then probed 
with an anti-myc antibody for input samples. 
 
Generation and purification of the Rhes antibody 
Rat Rhes was cloned into pGEX-4T2 and transformed into 
BL21-Codon Plus RIL cells (Stratagene). Bacterial cells 
were grown to an OD600 nm of 0.4 and protein production was 
stimulated with 1 mM IPTG overnight at room temperature. 
Cells were lysed in Buffer B (50 mM Tris pH 7.4, 150 mM 
NaCl, 2% Sarkosyl, 10% Glycerol, 2 mM EDTA, 5 mM DTT, 1 mM 
PMSF, 25 µg/ml antipain, 50 µg/ml leupeptin, 50 µg/ml 
aprotinin, 25 µg/ml chymostatin and 25 µg/ml pepstatin ) and 
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sonicated for 10 minutes. The supernatant was obtained 
after spinning at 20,000 x g for 20 minutes and Triton X-
100 was added to a final concentration of 1%. The protein 
was allowed to bind to glutathione sepharose overnight at 
4C and the beads were washed two times in Wash Buffer B 
(PBS, 10% Glycerol and 1% Triton) and then twice in Wash 
Buffer C (PBS and 10% Glycerol). Protein was eluted in 1 ml 
fractions in Elution Buffer (50 mM Tris pH 8.0, 150 mM 
NaCl, 10% Glycerol, 2 mM EDTA, 5 mM DTT, 20 mM reduced 
glutathione, 1 mM PMSF, 25 µg/ml antipain, 50 µg/ml 
leupeptin, 50 µg/ml aprotinin, 25 µg/ml chymostatin and 25 
µg/ml pepstatin) and sent to Cocalico Biologicals for 
antibody production. 
Polyclonal antibodies were generated in two rabbits and 
bleeds were obtained. The antibodies to GST in the serum 
were purified out using the protocol from the Flemington 
lab (www.flemingtonlab.com). The antibody was tested 
against GST or myc-tagged over-expressed proteins in HEK 
293T cells to show specificity to Rhes. Whole body tissue 
samples were obtained from C57/B6 mice, while brain region 
samples were obtained from Sprague-Dawley rats. In all 
cases, 100 µg of total protein was loaded onto 4-12% Bis-
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Tris gels, transferred and probed with the anti-Rhes 
antibody. 
 
Measurement of Cell Death 
To quantitatively measure cell death after stimulation with 
various agonists, we employed the MTT assay. A 5 mg/ml 
stock of MTT (Thiazolyl Blue Tetrazolium Bromide, Sigma, 
St. Louis) was diluted to a final concentration of 0.25 
mg/ml in HBSS buffer and added to cells after various 
treatments. Cells were incubated at 37C for 2 – 4 hours, 
then the MTT reagent was removed and the cells washed one 
time in HBSS. Healthy cells with intact mitochondria 
convert the yellow colored MTT reagent to purple crystals 
within the cells, which can then be dissolved in 0.1N HCl 
in isopropanol. The samples, measured in triplicate, were 
read in a spectrophotometer at OD 580 nm and OD 630 nm. The 
OD 580 nm – OD 630 nm reading was normalized to control and 
expressed as a percentage of cell viability. 
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CHAPTER 3: 
Results and Discussion 
 
Part 1: Dexras1 interacts with Peripheral Benzodiazepine 
Receptor Associated Protein (PAP7) 
Though it is known that Dexras1 interacts with nNOS 
and is activated by NO via S-nitrosylation, the function 
for this activated Dexras1 has not yet been determined. To 
elucidate physiological roles for Dexras1, we conducted 
yeast-two-hybrid analysis utilizing full length Dexras1 
fused to the GAL4 DNA binding domain, and a rat whole brain 
cDNA library fused to the GAL4 DNA activation domain. A 
single colony identified PAP7 as a potential interactor. 
PAP7 is a 62 kDa protein including several domains: an 
acyl-coenzyme A-binding protein signature, a bipartite 
nuclear localization signal at the N-terminus, a Golgi 
dynamics (GOLD) domain at the C-terminus and glutamate (E)-
, glutamine (Q)- and an asparagine (N)-rich domains (Figure 
5).  PAP7 was identified as an interacting protein of the 
peripheral benzodiazepine receptor (PBR) and may be 
involved in steroidogenesis in the mitochrondria. It also 
interacts with the regulatory subunit of PKA, though its 











Figure 5: Schematic diagram of PAP7 
 
An Acyl-CoA Binding Protein Domain (ACBP) and bipartite 
nuclear localization signal (NLS) are located at the N-
terminus, while a Golgi Dynamics (GOLD) Domain resides at 
the C-terminus. The middle of the protein contains 
asparagine (N), glutamate (E) and glutamine (Q)-rich 
domains. The Dexras1 binding domain is located between 
amino acids 193-444 as determined by yeast two-hybrid 
analysis.
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Part 1.1: Characterization of PAP7 
 
As little is known about PAP7 and its functions, we 
began by characterizing PAP7 proteins expression levels in 
tissues and in the brain. Western blot analysis reveals 
that PAP7 is expressed at substantial levels in multiple 
mouse tissues including brain, adrenal, heart, lunch, 
liver, spleen and testes, but no detectable levels in the 
kidney, while Dexras1 is brain-selective with modest levels 
in the heart and testes and nNOS is expressed only in the 
brain (Figure 6A). PAP7 is expressed ubiquitously in all 
regions of the brain (Figure 6B) and occurs in high levels 
in many different cell lines, with very low levels in HEK 
293T and HeLa cells (Figure 7). Immunohistochemical 
staining of PAP7 in undifferentiated PC12 cells shows that 
PAP7 is localized to the Golgi and to the cytosol (Figure 
8). Localization of PAP7 in Golgi, where it interacts with 
gigantin and was designated GCP60, has been previously 
reported (Sohda et al., 2001). 
As PAP7 interacts with PKA (Li et al., 2001), we 
wondered if PAP7 is phosphorylated. In vivo and in vitro 
phosphorylation experiments show that PAP7 is 
phosphorylated by CK2, not PKA, and is attenuated with 
treatment with TBB, a CK2 inhibitor (Figure 9A – 9D). Using 




Figure 6: Localization of PAP7 
(A) Western blot analysis shows that PAP7 is expressed at 
substantial levels in multiple mouse tissues, including the 
brain, adrenal, heart, lung, liver, spleen and testis but 
not in the kidney. Dexras1 is brain-specific with modest 
levels in the heart and testis, while nNOS is expressed 
only in the brain. 
(B) PAP7 is expressed ubiquitously in all regions of the 



















Figure 7: PAP7 expression in various cell lines 
PAP7 is expressed in many commonly used cell lines, 
including PC12 cells, the two neuroblastoma cell lines, N2a 
and N1E-11, the striatal cell line, M213-2O and COS7 cells 









Figure 8: Immunohistochemical localization of PAP7 
Undifferentiated PC12 cells were transfected with a Golgi 
marker and stained for endogenous PAP7, revealing that PAP7 
is localized to both the Golgi apparatus and the cytosol. 
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Figure 9: In vivo and in vitro phosphorylation of PAP7 
(A) HEK 293T cells were transfected with myc-tagged PAP7 
and labeled with 32P-orthophosphate in the presence or 
absence of various kinase inhibitors, revealing that PAP7 
is phosphorylated by CK2. Inhibitors (Kinase): 
Staurosporine (general Ser/Thr kinase), H-89 (PKA), GFX 
(PKC), TBB (CK2 – strong inhibitor), DRB (CK2 – weak 
inhibitor), Olomoucine (CDK5), SB216763 (GSK3β) and 
Indirubin-3-monoxime (GSK3β, CDK1, CDK5). The ratio of the 
densities of bands of the autoradiograph signal to 






B) Myc-tagged PAP7 was immunoprecipitated from 
transfected HEK 293T cells, treated with lambda 
phosphatase, then phosphorylated with various kinases, 
showing that CK2 specifically and robustly phosphorylates 
PAP7. This phosphorylation was significantly reduced both 
in vitro (C) and in vivo (D) with treatment of the samples 
with TBB. (E) In vivo phosphorylation experiments show that 
PAP7 is phosphorylated at the N- and C-terminus, but not in 
the middle of the protein. 
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phosphorylated at both the N- and C-terminus, but not in 
the middle of the protein and not in the region that 
interacts with Dexras1 (Figure 9E). The specific site and 
consequence of this phosphorylation is still unknown. 
 
Part 1.2: Interaction of Dexras1 and PAP7 
From the yeast-two hybrid, Dexras1 interacts with PAP7 
between amino acids 193-444, encompassing parts of the E-, 
Q- and N-rich domains, as well as the first part of the 
GOLD domain.  We have confirmed the Dexras1-PAP7 
interaction by transient transfections of GST-PAP7 and 
Dexras1-Myc in HEK 293T cells, which reveals selective 
binding of Dexras1 and PAP7 (Figure 10A). PAP7 also binds 
to a constitutively active form of Dexras1 (A178V)(Graham 
et al., 2001) at about the same level as while-type, 
indicating the activity status of Dexras1 is not important 
for protein interaction. In fact, Dexras1 has the ability 
to bind PAP7 even in the presence of 10 mM EDTA, which 
would chelate the Mg2+ from Dexras1 and render it nucleotide 
free (Figure 10B). 
We have narrowed down the binding region of Dexras1 on 
PAP7. Starting with the 193-444 region, which binds to 
Dexras1 (Figure 11A), we made deletion constructs of this 




Figure 10: Dexras1 binds to PAP7 in transfected HEK 293T 
cells 
 
(A) HEK 293T cells were transfected with GST or GST-PAP7 
and either wild-type or constitutively active (A178V) 
Dexras1. GST pulldown experiments show that both wild-type 
and A178V Dexras1 specifically binds to PAP7, in about 
equal amounts, suggesting that the activity status of 
Dexras1 does not affect binding. (B) Dexras1 is still able 
to bind to PAP7 in the presence of 10 mM EDTA, which would 




Figure 11: Narrowing down the Dexras1 binding region on 
PAP7 
 
(A) Yeast-two hybrid analysis revealed the Dexras1 binding 
region on PAP7 to be between amino acids 193-444, which was 
confirmed by GST pulldown experiments in HEK 293T cells. 
Deletion constructs were made within this region and the 
binding was narrowed down to a 50 amino acid region (B) 
between amino acids 393–444, then further narrowed to a 5 
amino acid region (C) between amino acids 414-419. 
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11B). Using this, we have determined that Dexras1 binds to 
PAP7 between amino acids 414-419 (Figure 11C). We have also 
narrowed down the binding region of PAP7 on Dexras1 to 
amino acids 96-101, close to the Mg2+ loop of the G-protein 
(Figure 12). 
Immunohistochemical staining of undifferentiated PC12 
cells reveals PAP7 is localized to the Golgi apparatus and 
to the cytosol, while Dexras1 is cytosolic and plasma 
membrane associated, so Dexras1 and PAP7 co-localize in the 
cytosol (Figure 13). 
 
Part 1.3: Dexras1, PAP7 and DMT1 participate in iron 
trafficking 
To evaluate the interaction of endogenous Dexras1 and 
PAP7, we employed PC12 cells, which contain high levels of 
both PAP7 and Dexras1. Using an antibody to Dexras1, we 
observe specific co-immunoprecipitation of PAP7 (Figure 
14A). An NCBI nucleotide sequence submission reported PAP7 
as interacting with DMT1 (NCBI accession number NM_182843), 
though no data had yet been shown to prove this. Using PC12 
cells and an antibody for DMT1, we have confirmed the 
binding of PAP7 and DMT1 by co-immunoprecipitation (Figure 
14B). To examine a more physiological preparation, we 




Figure 12: Narrowing down the PAP7 binding region on 
Dexras1 
 
(A) Deletion constructs of Dexras1 were made such that 
they overlapped with identical regions of Rhes and GST 
pulldown experiments were performed in HEK 293T cells. 
Initial studies showed that PAP7 binds to Dexras1 between 
amino acids 71-106, and the binding region was further 







Figure 13: Immunohistochemical co-localization of Dexras1 
and PAP7 
 
Undifferentiated PC12 cells were fixed and stained for 
endogenous Dexras1 and PAP7. Dexras1 is localized to the 
cytosol and plasma membrane, while PAP7 is localized to the 
cytosol and Golgi apparatus. 
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brain and examined for the presence of a ternary complex. 
Using an antibody to PAP7, we observe simultaneous co-
precipitation of both Dexras1 and DMT1 (Figure 14C). Thus, 
these three proteins appear to exist in a ternary complex 
in intact brain, suggesting that they may interact 
physiologically.  
DMT1 is the only known iron importer in the cell, and 
since PAP7 and Dexras1 binds to DMT1, we wondered whether 
Dexras1 and PAP7 influence iron homeostasis. Using HEK 293T 
cells, which contain very low levels of PAP7, we show that 
over-expression of wild-type Dexras1 very modestly augments 
NTBI uptake, which is substantially enhanced by co-
transfection with PAP7 (Figure 15). Thus, PAP7 is required 
for robust influence of Dexras1 on iron uptake. The action 
of Dexras1 on iron uptake derives from its GTPase actions, 
as a constitutively GTPase active form of Dexras1, with a 
mutation of alanine-178 to valine (A178V), increases iron 
uptake more than native Dexras1 in the presence or absence 
of PAP7.  
As NO S-nitrosylates and activates Dexras1, we 
examined effects of NO donors on iron uptake. Treatment of 
undifferentiated PC12 cells with S-nitrosoglutathione 
(GSNO) results in S-nitrosylation of Dexras1 (Figure 16A) 
and enhances NTBI uptake in a concentration dependent 
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Figure 14: Endogenous interaction of Dexras1 and PAP7 and 
DMT1 
 
(A) Immunoprecipitation experiments were performed using 
undifferentiated PC12 cells with a Dexras1 antibody, 
showing co-precipitation of PAP7. (B) Immunoprecipitation 
experiments were performed using undifferentiated PC12 
cells with a DMT1 antibody, showing co-precipitation of 
PAP7. (C) Immunoprecipitation experiments were performed 
using mouse brain lysate with a PAP7 antibody, showing 
simultaneous immunoprecipitation of Dexras1 and DMT1, 
suggesting that the three proteins exist in a ternary 






Figure 15: Over-expression of Dexras1 and PAP7 increases 
NTBI uptake 
 
HEK 293T cells were transfected with Dexras1 or Dexras1-
A178V in the presence or absence of PAP7. NTBI uptake was 
measured as described in the Materials and Methods. (*, 
p<0.05, **, p<0.01). Dexras1 and PAP7 together increase 
NTBI uptake, which is further augmented by the 
constitutively active Dexras1 mutant, A178V. (NTBI uptake 
experiments were repeated three times, each sample in 
triplicate. Comparison with two-tailed student’s t-test; 
error bars represent SEM). 
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manner (Figure 16B). Other NO donors, sodium nitroprusside 
(SNP)(Figure 16C) and DETANONOate (Figure 16D), elicit 
similar effects. As Dexras1 activation by S-nitrosylation 
involves cysteine-11 (Jaffrey et al., 2002), we examined 
the effects of a Dexras1 cysteine mutant (C11S) on NO-
mediated iron uptake. The C11S mutant still interacts with 
PAP7 (Figure 17A), however, in HEK 293T ells transfected 
with PAP7 and wild-type or C11S mutated Dexras1, the C11S 
mutation abolishes GSNO activation of NTBI uptake (Figure 
17B).  
To determine whether Dexras1 is required for NO-
mediated iron uptake, we sought to deplete Dexras1. Since 
it is difficult to transfect primary cortical neurons, we 
employed undifferentiated PC12 cells, which contain 
endogenous Dexras1, PAP7 and DMT1. We successfully depleted 
Dexras1 in PC12 cells using vector-based RNA interference 
(Figure 18A). While GSNO augments NTBI uptake in control 
PC12 cells, it fails to increase uptake in the Dexras1-
depleted cells (Figure 18B).  
Previous work from our lab showed that Dexras1 is 
activated by glutamate-NMDA neurotransmission acting via 
nNOS and NO. We examined the influence of NMDA upon iron 
uptake in primary cortical neuronal cultures. These 
experiments were conducted in a media that contained about 
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Figure 16: Dexras1 is S-nitrosylated and NTBI uptake is 
increased in PC12 cells after treatment with NO donors. 
 
(A) Dexras1 in undifferentiated PC12 cells is S-
nitrosylated by GSNO in a concentration-dependent manner 
(B) GSNO treatment for 3h leads to a concentration-
dependent increase NTBI uptake in undifferentiated PC12 
cells, as does (C) SNP for 1h and (D) DETA NONOate for 4h. 
(All NTBI uptake experiments were repeated three times, 
each sample in triplicate. Comparison with two-tailed 






Figure 17: NO-mediated NTBI uptake is mediated by S-
nitrosylation of Dexras1 
 
(A) HEK 293T cells were transfected with GST or GST-PAP7 
Dexras1-C11S-myc, a nitrosylation-dead mutant, which is 
able to bind specifically to PAP7. (B) HEK 293T cells were 
transfected with PAP7 and either wild-type Dexras1 or the 
C11S mutant. After transfection, the cells were treated 
with 100 µM GSNO for 3h and NTBI uptake was measured (*, 
p<0.01). GSNO treatment up-regulates NTBI uptake in cells 
containing wild-type Dexras1, but not the C11S mutant. 
(NTBI uptake experiments were repeated three times, each 
sample in triplicate. Comparison with two-tailed student’s 




Figure 18: Depletion of Dexras1 in PC12 cells abolishes NO-
mediated NTBI uptake 
 
(A) Undifferentiated PC12 cells were transfected with 
either control RNAi or Dexras1 RNAi (mock is 
untransfected). Dexras1 protein levels was fully depleted 
after transfection with Dexras1 RNAi, but not in control or 
mock-transfected cells (B) Undifferentiated PC12 cells were 
transfected with either control RNAi or Dexras1 RNAi, 
treated with 100 µM GSNO for 3h and NTBI uptake was measured 
(*, p<0.01). GSNO treatment up-regulates NTBI uptake in 
control cells, but not in cells depleted of Dexras1. (All 
NTBI uptake experiments were repeated three times, each 
sample in triplicate. Comparison with two-tailed student’s 
t-test; error bars represent SEM). 
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0.8 mM magnesium, a concentration which would be too low to 
impair NMDA neurotransmission and would not be expected to 
compete with iron uptake by DMT1 (Nowak et al., 1984; 
Picard et al., 2000). NMDA treatment increases NTBI uptake 
in a concentration-dependent manner (Figure 19A), with the 
effects blocked by pre-treatment with the NMDA antagonist 
MK801(+) (Figure 19C). NMDA fails to increase NTBI uptake 
in cultures from nNOS knockout mice, showing that nNOS and 
NO are required for NMDA-mediated NTBI uptake (Figure 19B 
and 19C). NMDA transmission augments calcium conductance 
though the NMDA receptor, which fits with the ability of 
the calcium ionophore, ionomycin, to stimulate NTBI uptake, 
and effect abolished in nNOS knockout cultures (Figure 
19B). 
 
Part 1.4: Physiological and Pathophysiological Relevance of 
Dexras1 Regulation of Iron Uptake 
Iron taken up through the Tf-mediated iron uptake 
pathway is used for physiological processes, such as heme 
synthesis. We examined whether the effects seen on NTBI 
uptake were mimicked in the Tf-iron uptake pathway. Using 
cortical neurons, we observed a concentration dependent 
uptake in Tf-iron uptake after NMDA treatment (Figure 20A). 
Tf-mediated iron uptake is also augments by treatment with 
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Figure 19: Glutamate-NMDA neurotransmission increases NTBI 
uptake, which is abolished in nNOS knockout mice 
 
(A) NMDA stimulation increases NTBI uptake in primary 
cortical neurons in a concentration-dependent manner. (B) 
NTBI uptake in primary cortical neurons is increased by 
both NMDA stimulation and ionomycin treatment, a calcium 
ionophore. This up-regulation is not seen in primary 
cortical neurons from nNOS knockout mice (*, p<0.05, **, 
p<0.01) and (C) is abolished by pre-treatment with MK801, 
an NMDA receptor antagonist (*, p<0.005). (All NTBI uptake 
experiments were repeated three times, each sample in 
triplicate. Comparison with two-tailed student’s t-test; 
error bars represent SEM). 
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ionomycin (Figure 20B), effects abolished by pre-treatment 
with MK801(+) or in nNOS knockout cultures (Figure 20B and 
20C). To assess the physiological relevance of NMDA-
stimulated iron uptake, we monitored 55Fe incorporation into 
heme in cortical cultures treated with NMDA. NMDA 
stimulation markedly increases the rate of heme 
biosynthesis (Figure 21A). Interestingly, when we measure 
the total heme content in brains of either wild-type or 
nNOS knockout mice, the nNOS knockout mice had a 25% 
decrease in total heme as compared to their wild-type 
counterparts, regardless of the age of the mice (Figure 
21B). 
We wondered whether the stimulation of iron uptake by 
NMDA neurotransmission might have pathophysiological 
consequences, as over-activation of NMDA receptors leads to 
neurotoxicity which has been implicated in vascular stroke 
and neurodegenerative diseases (Choi, 1994). In 
cerebrocortical cultures, a concentration of 0.3 mM NMDA is 
well established to elicit neurotoxicity (Dawson et al., 
1991; Koh and Choi, 1988). We have verified that this 
concentration of NMDA elicits a major augmentation in NTBI 
uptake (Figure 22A). As neurotoxicity is associated with a 
pronounced increase in reactive oxygen species (ROS), we 




Figure 20: Glutamate-NMDA neurotransmission increases Tf-
iron uptake, which is abolished in nNOS knockout mice 
 
(A) Tf-mediated iron uptake is increased in a dose-
dependent manner with NMDA treatment in primary cortical 
neurons. (B) Tf-mediated iron uptake is increased by both 
NMDA and ionomycin (*, p<0.01, **, p<0.01). This up-
regulation is not seen in primary cortical neurons from 
nNOS knockout mice and (C) is abolished by pre-treatment 
with MK801 (*, p<0.005). No increase in uptake is seen in 
neurons from nNOS knockout mice. (All Tf uptake experiments 
were repeated three times, each sample in triplicate. 




Figure 21: Physiological Relevance of Iron Uptake 
 
(A) Rate of heme biosynthesis was measured using 
incorporation of 55Fe into heme and was increased after NMDA 
treatment (*, p<0.01). (B) Total heme content of the brains 
of wild-type and nNOS knockout mice was measured using the 
HemoQuant assay, showing that there is a significant 
decrease in heme in the nNOS knockout mice, regardless of 
the age of the mice (*, p<0.01). (All experiments were 
repeated three times, each sample in triplicate. Comparison 
with two-tailed student’s t-test; error bars represent 
SEM). 
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detects hydroxyl free radicals (Setsukinai et al., 2003). 
These radicals predominantly arise from the Fenton reaction 
that typically reflects iron interacting with hydrogen 
peroxide to form hydroxyl free radicals. Treatment with 0.3 
mM NMDA elicits a 3.5 fold augmentation in hydroxyl free 
radical formation (Figure 22B). To determine whether this 
increase is caused by the Fenton reaction elicited by iron, 
we employed SIH (salicylaldehyde isonicotinoyl hydrazone), 
a selective cell permeable iron chelator. SIH treatment 
abolishes the increase in hydroxyl free radicals caused by 
NMDA, implying that the free radical formation arises from 
the iron whose influx is stimulated by NMDA (Figure 22B). 
 We also examined whether this influx of iron is 
involved in NMDA-mediated neurotoxicity. Preliminary 
experiments using primary hippocampal cultures show that 
0.3 mM NMDA treatment leads to a significant amount of 
neuronal cell death after 24 hours. This phenomenon is 
attenuated by pre-treatment with either MK801(+), NOS 
inhibitors, SIH or DFO (desferroxamine), a cell non-
permeable iron chelator (Figure 23). This suggests that 
iron could be the effector molecule of NMDA-induced cell 
death, working through nitric oxide. 
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Figure 22: Excitotoxic concentration of NMDA stimulates 
iron uptake and formation of reactive oxygen species 
 
(A) NTBI uptake is significantly increased after treatment 
with an excitotoxic concentration of NMDA. (B) An increase 
in HPF fluorescence was observed after treatment with NMDA, 
indicating an increase in ROS formation. This increase was 
abolished with pre-treatment of the neurons with SIH. 
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Figure 23: Iron chelators attenuate NMDA-induced cell death 
 
Primary hippocampal neurons were pretreated for three hours with 
the following: 10 µM MK801(+), an NMDA receptor antagonist, 500 
µM L-NAME + 100 µM Nω-Nitro-L-Arginine, nNOS inhibitors, 100 µM 
Salicylaldehyde isonicotinoyl hydrazone (SIH), a cell permeable 
iron chelator and 100 µM Desferrioxamine, a cell non-permeable 
iron chelator. The solutions were removed and the cells were 
treated with 300 µM NMDA for 10 minutes, then the cells were 
incubated for 24 hours before cell viability was assessed by 
propidium iodide staining. Pre-treatment of neurons with iron 
chelator significantly reduced cell death induced by NMDA. 
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We wondered whether the influx of iron was specific to NMDA 
and NO-induced cell death. Using undifferentiated PC12 
cells, we treated them with 0.5 mM GSNO, 0.2 mM H2O2 or 1 µM 
staurosporine (STS) overnight and observed an increase in 
NTBI uptake only with GSNO treatment (Figure 24A), 
indicating that not all agonists of cell death stimulate 
iron uptake. To examine whether Dexras1, which we have 
already shown influences NO-mediated iron uptake, 
participates in NO-mediated cell death, we depleted Dexras1 
from PC12 cells using RNA inteference, then treated with 
various cell death stimulants and measured cell viability. 
In cells depleted with Dexras1, GSNO-mediated cell death 
was attenuated, while cell death caused by H2O2 or STS was 
unaffected (Figure 24B). 
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Figure 24: NO-induced cell death is mediated by Dexras1 
 
(A) Undifferentiated PC12 cells were treated overnight 
with various stimulators of cell death and NTBI uptake 
measured. GSNO stimulated iron uptake, while H2O2 and 
staurosporine did not. (B) PC12 cells were double 
transfected with either control or Dexras1 RNAi, then 
treated overnight with GSNO or staurosporine. Cell 
viability was measured using the MTT assay and normalized 
to control. Depletion of Dexras1 rescued GSNO-mediated cell 
death, while staurosporine-induced cell death was 
unaffected. 
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Part 2: Characterization of Rhes and its interaction with 
PAP7 
 
 Little is known about Rhes, except that it is enriched 
in the striatum and that it is transcriptionally 
upregulated by thyroid hormone (Falk et al., 1999; Vargiu 
et al., 2001). Dexras1 is known to be regulated by NO, but 
no studies about NO regulation of Rhes have yet been 
undertaken. We have produced an antibody to Rhes and have 
examined its protein expression levels in the whole body 
and the brain. The antibody is specific to Rhes, and does 
not detect either GST or Dexras1 (Figure 25A). Rhes is 
localized to the brain, adrenal, lung, spleen and testis 
(Figure 25B) Within the brain, it is localized to the 
cerebellum, cortex, hippocampus and striatum (Figure 25C). 
Rhes is expressed at high levels in PC12 and COS7 cells, as 
well as the mouse M213-2O striatal cell line, and the two 
neuroblastoma cells lines N2a and N1E-11, but not in HEK 
293T or HeLa cells (Figure 25D).  
 As Rhes and Dexras1 share about 68% homology, we 
wondered if it was also regulated in a similar manner by 
nitric oxide and S-nitrosylation. Using the biotin switch 
assay (Jaffrey and Snyder, 2001), we transfected HEK 29T 
cells with myc-tagged Rhes and examined for the increase in 




Figure 25: Localization of Rhes 
(A) An antibody to Rhes was generated and was shown to be 
specific to Rhes using overexpressed protein in HEK 293T 
cells. (B) Using mouse tissue lysates, Rhes is shown to be 
localized to the brain, adrenal, lung, liver and testis. 
(C) Rhes is localized to various regions of the brain, 
including cerebellum, cortex, hippocampus, striatum and the 
olfactory bulb. (D) Rhes is localized to various cell 
lines, including PC12, N2a, N1E-11, COS7 and M213-2O cells, 
but not HEK 293T or HeLa  cells, while Dexras1 is present 
in only PC12 and N2a cells and nNOS is only present in N1E-
11 cells. 
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significant increase in biotin is seen after GSNO treatment 
of Dexras1, there is no increase in the biotin signal with 
Rhes, indicating that it is not nitrosylated (Figure 26). 
 We also examined whether Rhes can also bind to PAP7. 
We transiently transfected GST-PAP7 and Rhes-Myc in HEK 
293T cells, pulled down with glutathione sepharose and 
reveal Rhes and PAP7 specifically interact with one another 
(Figure 27A), even in the presence of 10 mM EDTA (Figure 
27B). Using deletion constructs of PAP7, we narrowed down 
the binding site of Rhes to amino acids 414-424 of PAP7, 
the same stretch of amino acids as Dexras1 (data not 
shown). We speculate, due to the high homology between 
Dexras1 and Rhes, that the binding region of PAP7 to Rhes 
will be the same as that of Dexras1, between amino acids 
96-101.  
We examined whether Rhes has a similar influence on 
iron uptake as that of Dexras1. Over expression of Rhes and 
PAP7 in HEK 293T cells significantly augments both NTBI 
(Figure 28A) and Tf-mediated iron uptake (Figure 28B). 
Though Rhes does not appear to be regulated by NO, perhaps 
it is involved in the regulation of iron uptake in other 







Figure 26: Rhes is not nitrosylated 
Myc-tagged constructs of Rhes and Dexras1 were transfected 
into HEK 293T cells. After 48 hours, cells were treated 
with 100 µM GSNO for 3 hours, and the biotin switch assay 
was performed to assess the nitrosylation state of the 
protein. While there is an increase in the biotin signal 
after GSNO treatment of Dexras1, no increase in signal is 





Figure 27: Rhes binds to PAP7 
 
(A) HEK 293T cells were transfected with GST or GST-PAP7 
and myc-tagged Rhes. GST pulldown experiments show that 
Rhes specifically binds to PAP7 and that (B) Rhes is still 
able to bind to PAP7 in the presence of 10 mM EDTA, which 
would render Rhes inactive. 
 80
 
Figure 28: Rhes and PAP7 over-expression stimulates both 
NTBI and Tf-mediated iron uptake 
 
(A) HEK 293T cells were transfected with Rhes in the 
presence or absence of PAP7. Rhes and PAP7 together 
increase NTBI uptake. (B) HEK 293T cells were transfected 
with Rhes in the presence or absence of PAP7. Rhes and PAP7 
together increase Tf-mediated iron uptake. 
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Part 3: Phosphorylation of Dexras1 and Rhes by PKA 
 
 PAP7 was also identified to interact with the 
regulatory subunit of PKA (Li et al., 2001), though its 
effects on PKA are unknown. PAP7 itself is not 
phosphorylated by PKA, so we wondered whether PKA has any 
effects on Dexras1 and Rhes with PAP7 acting as a connector 
molecule between PKA and the two proteins.  In vitro 
phosphorylation experiments show that both Dexras1 and Rhes 
are phosphorylated by PKA, an effect which is attenuated 
with treatment with H-89, a PKA inhibitor (Figure 29). 
Whether PAP7 plays a role in this phosphorylation, as well 
as the site of phosphorylation on both Dexras1 and Rhes, is 




Figure 29: Dexras1 and Rhes are phosphorylated by PKA 
(A) Myc-tagged Dexras1 and (B) Rhes was immunoprecipitated 
from transfected HEK 293T cells, treated with lambda 
phosphatase, then in vitro phosphorylated with various 
kinases, showing that PKA specifically and robustly 
phosphorylates PAP7. (C) This phosphorylation was 
significantly reduced with treatment of the samples with H-
89, a PKA inhibitor. 
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Part 4: Discussion 
 
In summary, we have identified a novel signaling cascade 
whereby neurotransmission regulates iron homeostasis 
(Figure 30). Glutamate, acting via NMDA receptors, 
activates nNOS to form NO, which leads to protein S-
nitrosylation (Bredt and Snyder, 1994; Hess et al., 2005; 
Li et al., 2001). This modification activates Dexras1 
which, by its link to PAP7, augments both Tf-mediated and 
NTBI uptake. PAP7 does not appear to have a direct 
influence on iron homeostasis, as its over-expression does 
not affect iron uptake, though it does potentiate Dexras1-
induced enhancement of iron uptake. Instead, it presumably 
serves as a scaffold bringing Dexras1 into proximity to 
DMT1. Stimulation of iron uptake by Dexras1 reflects its 
GTPase activity, as constitutively active Dexras1 manifests 
enhanced activity in stimulating iron uptake. The influence 
of Dexras1 upon iron uptake is evidently the first example 
of a G-protein regulating an iron transporter. 
The molecular mechanism whereby Dexras1 and its GTPase 
activity regulate signaling via PAP7 and DMT1 is unclear. 
We presume that Dexras1 influences DMT1 directly but cannot 
rule out some action upon PAP7. Conceivably, other reported 
activities of Dexras1 may participate. For instance, 
Dexras1 activates the ERK1,2 pathway in a pertussis toxin 
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Figure 30: Dexras1, PAP7 and DMT1 mediate both NTBI and Tf-
mediated iron uptake 
 
A model of a signaling cascade whereby glutamate-NMDA 
neurotransmission regulates cellular iron homeostasis. 
Glutamate-NMDA stimulation leads to the activation of nNOS 
and, via the scaffolding protein CAPON, to S-nitrosylation 
of Dexras1, which interacts with PAP7 and DMT1 both at the 
endosome and the plasma membrane, thus influencing cellular 
iron uptake in the cell. 
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sensitive fashion (Cismowski et al., 2000). It impairs 
activation of G-protein coupled receptors that act via Gi, 
inhibiting adenylyl cylase (Graham et al., 2004). 
Functional relevance of those effects is suggested by its 
involvement in regulating circadian rhythm. Dexras1 
expression cycles in a circadian fashion in the 
suprachiasmatic nucleus (Takahashi et al., 2003). Its 
genetic deletion reduces photic entrainment of circadian 
responses to glutamate-NMDA transmission (Cheng et al., 
2004b). We have recently made a conditional Dexras1 
knockout mouse and plan to examine whether it has any gross 
hematological defects. We postulate that the Dexras1 
knockout mice will have defects in glutamate-NMDA induced 
iron uptake and wonder if neurons from these mice will be 
resistant to NMDA-induced excitotoxicity. 
Rhes is a homologue of Dexras1 and is induced by 
thyroid hormone, an interesting contrast to the stimulation 
of Dexras1 by glucocorticoids (Falk et al., 1999; Vargiu et 
al., 2001). Rhes is selectively localized to the corpus 
striatum. It also binds to PAP7 and regulates iron uptake 
into the cell, but does not appear to be regulated by nNOS 
and NO in the same fashion as that of Dexras1. Perhaps Rhes 
regulates iron uptake stimulated through other yet unknown 
pathways. 
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Iron is required for many physiological processes, 
such as heme synthesis, mitochondrial oxidation reactions 
and DNA synthesis, but is toxic in excess, so that its 
cellular disposition is tightly regulated. Studies of iron 
in the brain have largely focused on its pathophysiological 
roles, with iron accumulation occurring in numerous 
neurodegenerative diseases. Heretofore, no influence of 
neurotransmission upon iron uptake has been reported. Our 
findings establish a physiologic role for glutamate 
neurotransmission is regulating iron uptake in the brain in 





 1.  Abboud,S. and Haile,D.J. (2000). A novel mammalian 
iron-regulated protein involved in intracellular iron 
metabolism. J. Biol. Chem. 275, 19906-19912. 
 2.  Aisen,P. and Listowsky,I. (1980). Iron transport and 
storage proteins. Annu. Rev. Biochem. 49, 357-393. 
 3.  Anderson,B.F., Baker,H.M., Norris,G.E., Rice,D.W., and 
Baker,E.N. (1989). Structure of human lactoferrin: 
crystallographic structure analysis and refinement at 
2.8 A resolution. J. Mol. Biol. 209, 711-734. 
 4.  Andrews,N.C. (1999). Disorders of iron metabolism. N. 
Engl. J. Med. 341, 1986-1995. 
 5.  Andrews,N.C. (2000). Iron homeostasis: insights from 
genetics and animal models. Nat. Rev. Genet. 1, 208-
217. 
 6.  Bacon,B.R. and Britton,R.S. (1990). The pathology of 
hepatic iron overload: a free radical--mediated 
process? Hepatology 11, 127-137. 
 7.  Bailey,S., Evans,R.W., Garratt,R.C., Gorinsky,B., 
Hasnain,S., Horsburgh,C., Jhoti,H., Lindley,P.F., 
Mydin,A., Sarra,R., and . (1988). Molecular structure 
of serum transferrin at 3.3-A resolution. Biochemistry 
27, 5804-5812. 
 8.  Baker,E.N. and Lindley,P.F. (1992). New perspectives 
on the structure and function of transferrins. J. 
Inorg. Biochem. 47, 147-160. 
 9.  Bredt,D.S., Hwang,P.M., and Snyder,S.H. (1990). 
Localization of nitric oxide synthase indicating a 
neural role for nitric oxide. Nature 347, 768-770. 
 10.  Bredt,D.S. and Snyder,S.H. (1989). Nitric oxide 
mediates glutamate-linked enhancement of cGMP levels 
in the cerebellum. Proc. Natl. Acad. Sci. U. S. A 86, 
9030-9033. 
 11.  Bredt,D.S. and Snyder,S.H. (1990). Isolation of nitric 
oxide synthetase, a calmodulin-requiring enzyme. Proc. 
Natl. Acad. Sci. U. S. A 87, 682-685. 
 88
 12.  Bredt,D.S. and Snyder,S.H. (1994). Nitric oxide: a 
physiologic messenger molecule. Annu. Rev. Biochem. 
63, 175-195. 
 13.  Bridges,K.R. (1987). Ascorbic acid inhibits lysosomal 
autophagy of ferritin. J. Biol. Chem. 262, 14773-
14778. 
 14.  Burdo,J.R. and Connor,J.R. (2003). Brain iron uptake 
and homeostatic mechanisms: an overview. Biometals 16, 
63-75. 
 15.  Cellier,M., Prive,G., Belouchi,A., Kwan,T., 
Rodrigues,V., Chia,W., and Gros,P. (1995). Nramp 
defines a family of membrane proteins. Proc. Natl. 
Acad. Sci. U. S. A 92, 10089-10093. 
 16.  Cheng,H.Y., Obrietan,K., Cain,S.W., Lee,B.Y., 
Agostino,P.V., Joza,N.A., Harrington,M.E., Ralph,M.R., 
and Penninger,J.M. (2004a). Dexras1 potentiates photic 
and suppresses nonphotic responses of the circadian 
clock. Neuron 43, 715-728. 
 17.  Cheng,Y., Zak,O., Aisen,P., Harrison,S.C., and Walz,T. 
(2004b). Structure of the human transferrin receptor-
transferrin complex. Cell 116, 565-576. 
 18.  Choi,D.W. (1994). Glutamate receptors and the 
induction of excitotoxic neuronal death. Prog. Brain 
Res. 100, 47-51. 
 19.  Cismowski,M.J., Ma,C., Ribas,C., Xie,X., Spruyt,M., 
Lizano,J.S., Lanier,S.M., and Duzic,E. (2000). 
Activation of heterotrimeric G-protein signaling by a 
ras-related protein. Implications for signal 
integration. J. Biol. Chem. 275, 23421-23424. 
 20.  Cismowski,M.J., Takesono,A., Bernard,M.L., Duzic,E., 
and Lanier,S.M. (2001). Receptor-independent 
activators of heterotrimeric G-proteins. Life Sci. 68, 
2301-2308. 
 21.  Collawn,J.F., Lai,A., Domingo,D., Fitch,M., Hatton,S., 
and Trowbridge,I.S. (1993). YTRF is the conserved 
internalization signal of the transferrin receptor, 
and a second YTRF signal at position 31-34 enhances 
endocytosis. J. Biol. Chem. 268, 21686-21692. 
 89
 22.  Conrad,M.E. and Umbreit,J.N. (1993). A concise review: 
iron absorption--the mucin-mobilferrin-integrin 
pathway. A competitive pathway for metal absorption. 
Am. J. Hematol. 42, 67-73. 
 23.  Dautry-Varsat,A., Ciechanover,A., and Lodish,H.F. 
(1983). pH and the recycling of transferrin during 
receptor-mediated endocytosis. Proc. Natl. Acad. Sci. 
U. S. A 80, 2258-2262. 
 24.  Dawson,V.L., Dawson,T.M., London,E.D., Bredt,D.S., and 
Snyder,S.H. (1991). Nitric oxide mediates glutamate 
neurotoxicity in primary cortical cultures. Proc. 
Natl. Acad. Sci. U. S. A 88, 6368-6371. 
 25.  Donovan,A. and Andrews,N.C. (2004). The molecular 
regulation of iron metabolism. Hematol. J. 5, 373-380. 
 26.  Donovan,A., Brownlie,A., Zhou,Y., Shepard,J., 
Pratt,S.J., Moynihan,J., Paw,B.H., Drejer,A., 
Barut,B., Zapata,A., Law,T.C., Brugnara,C., Lux,S.E., 
Pinkus,G.S., Pinkus,J.L., Kingsley,P.D., Palis,J., 
Fleming,M.D., Andrews,N.C., and Zon,L.I. (2000). 
Positional cloning of zebrafish ferroportin1 
identifies a conserved vertebrate iron exporter. 
Nature 403, 776-781. 
 27.  Drysdale,J.W. (1988). Human ferritin gene expression. 
Prog. Nucleic Acid Res. Mol. Biol. 35, 127-172. 
 28.  Eisenstein,R.S. (2000). Iron regulatory proteins and 
the molecular control of mammalian iron metabolism. 
Annu. Rev. Nutr. 20, 627-662. 
 29.  Falk,J.D., Vargiu,P., Foye,P.E., Usui,H., Perez,J., 
Danielson,P.E., Lerner,D.L., Bernal,J., and 
Sutcliffe,J.G. (1999). Rhes: A striatal-specific Ras 
homolog related to Dexras1. J. Neurosci. Res. 57, 782-
788. 
 30.  Fang,M., Jaffrey,S.R., Sawa,A., Ye,K., Luo,X., and 
Snyder,S.H. (2000). Dexras1: a G protein specifically 
coupled to neuronal nitric oxide synthase via CAPON. 
Neuron 28, 183-193. 
 31.  Farcich,E.A. and Morgan,E.H. (1992). Uptake of 
transferrin-bound and nontransferrin-bound iron by 
reticulocytes from the Belgrade laboratory rat: 
 90
comparison with Wistar rat transferrin and 
reticulocytes. Am. J. Hematol. 39, 9-14. 
 32.  Finch,C.A., Huebers,H., Eng,M., and Miller,L. (1982). 
Effect of transfused reticulocytes on iron exchange. 
Blood 59, 364-369. 
 33.  Fleming,M.D., Romano,M.A., Su,M.A., Garrick,L.M., 
Garrick,M.D., and Andrews,N.C. (1998). Nramp2 is 
mutated in the anemic Belgrade (b) rat: evidence of a 
role for Nramp2 in endosomal iron transport. Proc. 
Natl. Acad. Sci. U. S. A 95, 1148-1153. 
 34.  Fleming,M.D., Trenor,C.C., III, Su,M.A., Foernzler,D., 
Beier,D.R., Dietrich,W.F., and Andrews,N.C. (1997). 
Microcytic anaemia mice have a mutation in Nramp2, a 
candidate iron transporter gene. Nat. Genet. 16, 383-
386. 
 35.  Furchgott,R.F. and Zawadzki,J.V. (1980). The 
obligatory role of endothelial cells in the relaxation 
of arterial smooth muscle by acetylcholine. Nature 
288, 373-376. 
 36.  Garrick,L.M., Dolan,K.G., Romano,M.A., and 
Garrick,M.D. (1999). Non-transferrin-bound iron uptake 
in Belgrade and normal rat erythroid cells. J. Cell 
Physiol 178, 349-358. 
 37.  Girones,N., Alverez,E., Seth,A., Lin,I.M., 
Latour,D.A., and Davis,R.J. (1991). Mutational 
analysis of the cytoplasmic tail of the human 
transferrin receptor. Identification of a sub-domain 
that is required for rapid endocytosis. J. Biol. Chem. 
266, 19006-19012. 
 38.  Graham,T.E., Key,T.A., Kilpatrick,K., and Dorin,R.I. 
(2001). Dexras1/AGS-1, a steroid hormone-induced 
guanosine triphosphate-binding protein, inhibits 
3',5'-cyclic adenosine monophosphate-stimulated 
secretion in AtT-20 corticotroph cells. Endocrinology 
142, 2631-2640. 
 39.  Graham,T.E., Prossnitz,E.R., and Dorin,R.I. (2002). 
Dexras1/AGS-1 inhibits signal transduction from the 
Gi-coupled formyl peptide receptor to Erk-1/2 MAP 
kinases. J. Biol. Chem. 277, 10876-10882. 
 91
 40.  Graham,T.E., Qiao,Z., and Dorin,R.I. (2004). Dexras1 
inhibits adenylyl cyclase. Biochem. Biophys. Res. 
Commun. 316, 307-312. 
 41.  Gray,N.K. and Hentze,M.W. (1994). Iron regulatory 
protein prevents binding of the 43S translation pre-
initiation complex to ferritin and eALAS mRNAs. EMBO 
J. 13, 3882-3891. 
 42.  Gunshin,H., Allerson,C.R., Polycarpou-Schwarz,M., 
Rofts,A., Rogers,J.T., Kishi,F., Hentze,M.W., 
Rouault,T.A., Andrews,N.C., and Hediger,M.A. (2001). 
Iron-dependent regulation of the divalent metal ion 
transporter. FEBS Lett. 509, 309-316. 
 43.  Gunshin,H., Mackenzie,B., Berger,U.V., Gunshin,Y., 
Romero,M.F., Boron,W.F., Nussberger,S., Gollan,J.L., 
and Hediger,M.A. (1997). Cloning and characterization 
of a mammalian proton-coupled metal-ion transporter. 
Nature 388, 482-488. 
 44.  Gutteridge,J.M., Rowley,D.A., and Halliwell,B. (1981). 
Superoxide-dependent formation of hydroxyl radicals in 
the presence of iron salts. Detection of 'free' iron 
in biological systems by using bleomycin-dependent 
degradation of DNA. Biochem. J. 199, 263-265. 
 45.  Haile,D.J., Rouault,T.A., Tang,C.K., Chin,J., 
Harford,J.B., and Klausner,R.D. (1992). Reciprocal 
control of RNA-binding and aconitase activity in the 
regulation of the iron-responsive element binding 
protein: role of the iron-sulfur cluster. Proc. Natl. 
Acad. Sci. U. S. A 89, 7536-7540. 
 46.  Harford,J.B., Rouault,T.A., and Klausner,R.D. (1994). 
The Molecular Basis of Blood Diseases. (Philadelphia: 
WB Saunders Co.). 
 47.  Harris,Z.L., Durley,A.P., Man,T.K., and Gitlin,J.D. 
(1999). Targeted gene disruption reveals an essential 
role for ceruloplasmin in cellular iron efflux. Proc. 
Natl. Acad. Sci. U. S. A 96, 10812-10817. 
 48.  Harrison,P.M. (1977). Ferritin: an iron-storage 
molecule. Semin. Hematol. 14, 55-70. 
 49.  Hayes,G.R., Enns,C.A., and Lucas,J.J. (1992). 
Identification of the O-linked glycosylation site of 
 92
the human transferrin receptor. Glycobiology 2, 355-
359. 
 50.  Hentze,M.W. and Kuhn,L.C. (1996). Molecular control of 
vertebrate iron metabolism: mRNA-based regulatory 
circuits operated by iron, nitric oxide, and oxidative 
stress. Proc. Natl. Acad. Sci. U. S. A 93, 8175-8182. 
 51.  Hentze,M.W., Muckenthaler,M.U., and Andrews,N.C. 
(2004). Balancing acts: molecular control of mammalian 
iron metabolism. Cell 117, 285-297. 
 52.  Hess,D.T., Matsumoto,A., Kim,S.O., Marshall,H.E., and 
Stamler,J.S. (2005). Protein S-nitrosylation: purview 
and parameters. Nat. Rev. Mol. Cell Biol. 6, 150-166. 
 53.  Hibbs,J.B., Jr., Taintor,R.R., and Vavrin,Z. (1987). 
Macrophage cytotoxicity: role for L-arginine deiminase 
and imino nitrogen oxidation to nitrite. Science 235, 
473-476. 
 54.  Hubert,N. and Hentze,M.W. (2002). Previously 
uncharacterized isoforms of divalent metal transporter 
(DMT)-1: implications for regulation and cellular 
function. Proc. Natl. Acad. Sci. U. S. A 99, 12345-
12350. 
 55.  Huebers,H.A., Huebers,E., Csiba,E., and Finch,C.A. 
(1984). Heterogeneity of the plasma iron pool: 
explanation of the Fletcher-Huehns phenomenon. Am. J. 
Physiol 247, R280-R283. 
 56.  Iacopetta,B.J. and Morgan,E.H. (1983). The kinetics of 
transferrin endocytosis and iron uptake from 
transferrin in rabbit reticulocytes. J. Biol. Chem. 
258, 9108-9115. 
 57.  Ignarro,L.J., Buga,G.M., Wood,K.S., Byrns,R.E., and 
Chaudhuri,G. (1987). Endothelium-derived relaxing 
factor produced and released from artery and vein is 
nitric oxide. Proc. Natl. Acad. Sci. U. S. A 84, 9265-
9269. 
 58.  Jaffrey,S.R., Fang,M., and Snyder,S.H. (2002). 
Nitrosopeptide mapping: a novel methodology reveals s-
nitrosylation of dexras1 on a single cysteine residue. 
Chem. Biol. 9, 1329-1335. 
 93
 59.  Jaffrey,S.R., Snowman,A.M., Eliasson,M.J., Cohen,N.A., 
and Snyder,S.H. (1998). CAPON: a protein associated 
with neuronal nitric oxide synthase that regulates its 
interactions with PSD95. Neuron 20, 115-124. 
 60.  Jaffrey,S.R. and Snyder,S.H. (2001). The biotin switch 
method for the detection of S-nitrosylated proteins. 
Sci. STKE. 2001, L1. 
 61.  JANDL,J.H. and KATZ,J.H. (1963). The plasma-to-cell 
cycle of transferrin. J. Clin. Invest 42, 314-326. 
 62.  Kang,D.K., Jeong,J., Drake,S.K., Wehr,N.B., 
Rouault,T.A., and Levine,R.L. (2003). Iron regulatory 
protein 2 as iron sensor. Iron-dependent oxidative 
modification of cysteine. J. Biol. Chem. 278, 14857-
14864. 
 63.  Kaptain,S., Downey,W.E., Tang,C., Philpott,C., 
Haile,D., Orloff,D.G., Harford,J.B., Rouault,T.A., and 
Klausner,R.D. (1991). A regulated RNA binding protein 
also possesses aconitase activity. Proc. Natl. Acad. 
Sci. U. S. A 88, 10109-10113. 
 64.  Karin,M. and Mintz,B. (1981). Receptor-mediated 
endocytosis of transferrin in developmentally 
totipotent mouse teratocarcinoma stem cells. J. Biol. 
Chem. 256, 3245-3252. 
 65.  Kemppainen,R.J. and Behrend,E.N. (1998). Dexamethasone 
rapidly induces a novel ras superfamily member-related 
gene in AtT-20 cells. J. Biol. Chem. 273, 3129-3131. 
 66.  Kim,S. and Ponka,P. (2002). Nitrogen monoxide-mediated 
control of ferritin synthesis: implications for 
macrophage iron homeostasis. Proc. Natl. Acad. Sci. U. 
S. A 99, 12214-12219. 
 67.  Klausner,R.D., Van,R.J., Ashwell,G., Kempf,C., 
Schechter,A.N., Dean,A., and Bridges,K.R. (1983). 
Receptor-mediated endocytosis of transferrin in K562 
cells. J. Biol. Chem. 258, 4715-4724. 
 68.  Koh,J.Y. and Choi,D.W. (1988). Vulnerability of 
cultured cortical neurons to damage by excitotoxins: 
differential susceptibility of neurons containing 
NADPH-diaphorase. J. Neurosci. 8, 2153-2163. 
 94
 69.  Krishnamurthy,P., Ross,D.D., Nakanishi,T., Bailey-
Dell,K., Zhou,S., Mercer,K.E., Sarkadi,B., 
Sorrentino,B.P., and Schuetz,J.D. (2004). The stem 
cell marker Bcrp/ABCG2 enhances hypoxic cell survival 
through interactions with heme. J. Biol. Chem. 279, 
24218-24225. 
 70.  LaVaute,T., Smith,S., Cooperman,S., Iwai,K., Land,W., 
Meyron-Holtz,E., Drake,S.K., Miller,G., bu-Asab,M., 
Tsokos,M., Switzer,R., III, Grinberg,A., Love,P., 
Tresser,N., and Rouault,T.A. (2001). Targeted deletion 
of the gene encoding iron regulatory protein-2 causes 
misregulation of iron metabolism and neurodegenerative 
disease in mice. Nat. Genet. 27, 209-214. 
 71.  Lawson,D.M., Artymiuk,P.J., Yewdall,S.J., Smith,J.M., 
Livingstone,J.C., Treffry,A., Luzzago,A., Levi,S., 
Arosio,P., Cesareni,G., and . (1991). Solving the 
structure of human H ferritin by genetically 
engineering intermolecular crystal contacts. Nature 
349, 541-544. 
 72.  Levi,S., Luzzago,A., Cesareni,G., Cozzi,A., 
Franceschinelli,F., Albertini,A., and Arosio,P. 
(1988). Mechanism of ferritin iron uptake: activity of 
the H-chain and deletion mapping of the ferro-oxidase 
site. A study of iron uptake and ferro-oxidase 
activity of human liver, recombinant H-chain 
ferritins, and of two H-chain deletion mutants. J. 
Biol. Chem. 263, 18086-18092. 
 73.  Li,H., Degenhardt,B., Tobin,D., Yao,Z.X., Tasken,K., 
and Papadopoulos,V. (2001). Identification, 
localization, and function in steroidogenesis of PAP7: 
a peripheral-type benzodiazepine receptor- and PKA 
(RIalpha)-associated protein. Mol. Endocrinol. 15, 
2211-2228. 
 74.  McCance,R.A. and Widdowson,E.M. (1938). The absorption 
and excretion of iron following oral and intravenous 
administration. J. Physiol 94, 148. 
 75.  McClarty,G.A., Chan,A.K., Choy,B.K., and Wright,J.A. 
(1990). Increased ferritin gene expression is 
associated with increased ribonucleotide reductase 
gene expression and the establishment of hydroxyurea 
resistance in mammalian cells. J. Biol. Chem. 265, 
7539-7547. 
 95
 76.  McGraw,T.E. and Maxfield,F.R. (1990). Human 
transferrin receptor internalization is partially 
dependent upon an aromatic amino acid on the 
cytoplasmic domain. Cell Regul. 1, 369-377. 
 77.  McKie,A.T., Marciani,P., Rolfs,A., Brennan,K., 
Wehr,K., Barrow,D., Miret,S., Bomford,A., Peters,T.J., 
Farzaneh,F., Hediger,M.A., Hentze,M.W., and 
Simpson,R.J. (2000). A novel duodenal iron-regulated 
transporter, IREG1, implicated in the basolateral 
transfer of iron to the circulation. Mol. Cell 5, 299-
309. 
 78.  Moos,T. and Morgan,E.H. (1998). Evidence for low 
molecular weight, non-transferrin-bound iron in rat 
brain and cerebrospinal fluid. J. Neurosci. Res. 54, 
486-494. 
 79.  Muir,A. and Hopfer,U. (1985). Regional specificity of 
iron uptake by small intestinal brush-border membranes 
from normal and iron-deficient mice. Am. J. Physiol 
248, G376-G379. 
 80.  Nicolas,G., Chauvet,C., Viatte,L., Danan,J.L., 
Bigard,X., Devaux,I., Beaumont,C., Kahn,A., and 
Vaulont,S. (2002). The gene encoding the iron 
regulatory peptide hepcidin is regulated by anemia, 
hypoxia, and inflammation. J. Clin. Invest 110, 1037-
1044. 
 81.  Nowak,L., Bregestovski,P., Ascher,P., Herbet,A., and 
Prochiantz,A. (1984). Magnesium gates glutamate-
activated channels in mouse central neurones. Nature 
307, 462-465. 
 82.  Palmer,R.M., Ferrige,A.G., and Moncada,S. (1987). 
Nitric oxide release accounts for the biological 
activity of endothelium-derived relaxing factor. 
Nature 327, 524-526. 
 83.  Paterson,S., Armstrong,N.J., Iacopetta,B.J., 
McArdle,H.J., and Morgan,E.H. (1984). Intravesicular 
pH and iron uptake by immature erythroid cells. J. 
Cell Physiol 120, 225-232. 
 84.  Pattanapanyasat,K., Hoy,T.G., and Jacobs,A. (1987). 
The response of intracellular and surface ferritin 
 96
after T-cell stimulation in vitro. Clin. Sci. (Lond) 
73, 605-611. 
 85.  Picard,V., Govoni,G., Jabado,N., and Gros,P. (2000). 
Nramp 2 (DCT1/DMT1) expressed at the plasma membrane 
transports iron and other divalent cations into a 
calcein-accessible cytoplasmic pool. J. Biol. Chem. 
275, 35738-35745. 
 86.  Ponka,P. (2004). Hereditary causes of disturbed iron 
homeostasis in the central nervous system. Ann. N. Y. 
Acad. Sci. 1012, 267-281. 
 87.  Quigley,J.G., Yang,Z., Worthington,M.T., 
Phillips,J.D., Sabo,K.M., Sabath,D.E., Berg,C.L., 
Sassa,S., Wood,B.L., and Abkowitz,J.L. (2004). 
Identification of a human heme exporter that is 
essential for erythropoiesis. Cell 118, 757-766. 
 88.  Raffin,S.B., Woo,C.H., Roost,K.T., Price,D.C., and 
Schmid,R. (1974). Intestinal absorption of hemoglobin 
iron-heme cleavage by mucosal heme oxygenase. J. Clin. 
Invest 54, 1344-1352. 
 89.  Richardson,D.R. and Ponka,P. (1997). The molecular 
mechanisms of the metabolism and transport of iron in 
normal and neoplastic cells. Biochim. Biophys. Acta 
1331, 1-40. 
 90.  Riedel,H.D., Remus,A.J., Fitscher,B.A., and 
Stremmel,W. (1995). Characterization and partial 
purification of a ferrireductase from human duodenal 
microvillus membranes. Biochem. J. 309 ( Pt 3), 745-
748. 
 91.  Rothenberger,S., Iacopetta,B.J., and Kuhn,L.C. (1987). 
Endocytosis of the transferrin receptor requires the 
cytoplasmic domain but not its phosphorylation site. 
Cell 49, 423-431. 
 92.  Rouault,T.A. (2001). Systemic iron metabolism: a 
review and implications for brain iron metabolism. 
Pediatr. Neurol. 25, 130-137. 
 93.  Sawyer,S.T. and Krantz,S.B. (1986). Transferrin 
receptor number, synthesis, and endocytosis during 
erythropoietin-induced maturation of Friend virus-
 97
infected erythroid cells. J. Biol. Chem. 261, 9187-
9195. 
 94.  Schwartz,S., Dahl,J., Ellefson,M., and Ahlquist,D. 
(1983). The "HemoQuant" test: a specific and 
quantitative determination of heme (hemoglobin) in 
feces and other materials. Clin. Chem. 29, 2061-2067. 
 95.  Setsukinai,K., Urano,Y., Kakinuma,K., Majima,H.J., and 
Nagano,T. (2003). Development of novel fluorescence 
probes that can reliably detect reactive oxygen 
species and distinguish specific species. J. Biol. 
Chem. 278, 3170-3175. 
 96.  Shayeghi,M., Latunde-Dada,G.O., Oakhill,J.S., 
Laftah,A.H., Takeuchi,K., Halliday,N., Khan,Y., 
Warley,A., McCann,F.E., Hider,R.C., Frazer,D.M., 
Anderson,G.J., Vulpe,C.D., Simpson,R.J., and 
McKie,A.T. (2005). Identification of an intestinal 
heme transporter. Cell 122, 789-801. 
 97.  Shoham,S. and Youdim,M.B. (2000). Iron involvement in 
neural damage and microgliosis in models of 
neurodegenerative diseases. Cell Mol. Biol. (Noisy. -
le-grand) 46, 743-760. 
 98.  Shongwe,M.S., Smith,C.A., Ainscough,E.W., Baker,H.M., 
Brodie,A.M., and Baker,E.N. (1992). Anion binding by 
human lactoferrin: results from crystallographic and 
physicochemical studies. Biochemistry 31, 4451-4458. 
 99.  Sohda,M., Misumi,Y., Yamamoto,A., Yano,A., 
Nakamura,N., and Ikehara,Y. (2001). Identification and 
characterization of a novel Golgi protein, GCP60, that 
interacts with the integral membrane protein giantin. 
J. Biol. Chem. 276, 45298-45306. 
100. Sorond,F.A. and Ratan,R.R. (2000). Ironing-out 
mechanisms of neuronal injury under hypoxic-ischemic 
conditions and potential role of iron chelators as 
neuroprotective agents. Antioxid. Redox. Signal. 2, 
421-436. 
101. Spano,D., Branchi,I., Rosica,A., Pirro,M.T., 
Riccio,A., Mithbaokar,P., Affuso,A., Arra,C., 
Campolongo,P., Terracciano,D., Macchia,V., Bernal,J., 
Alleva,E., and Di,L.R. (2004). Rhes is involved in 
striatal function. Mol. Cell Biol. 24, 5788-5796. 
 98
102. Stein,B.S. and Sussman,H.H. (1986). Demonstration of 
two distinct transferrin receptor recycling pathways 
and transferrin-independent receptor internalization 
in K562 cells. J. Biol. Chem. 261, 10319-10331. 
103. Stuehr,D.J. and Nathan,C.F. (1989). Nitric oxide. A 
macrophage product responsible for cytostasis and 
respiratory inhibition in tumor target cells. J. Exp. 
Med. 169, 1543-1555. 
104. Takahashi,H., Umeda,N., Tsutsumi,Y., Fukumura,R., 
Ohkaze,H., Sujino,M., van der,H.G., Yasui,A., 
Inouye,S.T., Fujimori,A., Ohhata,T., Araki,R., and 
Abe,M. (2003). Mouse dexamethasone-induced RAS protein 
1 gene is expressed in a circadian rhythmic manner in 
the suprachiasmatic nucleus. Brain Res. Mol. Brain 
Res. 110, 1-6. 
105. Theil,E.C. (1987). Ferritin: structure, gene 
regulation, and cellular function in animals, plants, 
and microorganisms. Annu. Rev. Biochem. 56, 289-315. 
106. Thomas,M. and Jankovic,J. (2004). Neurodegenerative 
disease and iron storage in the brain. Curr. Opin. 
Neurol. 17, 437-442. 
107. Torti,F.M. and Torti,S.V. (2002). Regulation of 
ferritin genes and protein. Blood 99, 3505-3516. 
108. Van,R.J., Bridges,K.R., Harford,J.B., and 
Klausner,R.D. (1982). Receptor-mediated endocytosis of 
transferrin and the uptake of fe in K562 cells: 
identification of a nonlysosomal acidic compartment. 
Proc. Natl. Acad. Sci. U. S. A 79, 6186-6190. 
109. Vargiu,P., De,A.R., Garcia-Ranea,J.A., Valencia,A., 
Santisteban,P., Crespo,P., and Bernal,J. (2004). The 
small GTP-binding protein, Rhes, regulates signal 
transduction from G protein-coupled receptors. 
Oncogene 23, 559-568. 
110. Vargiu,P., Morte,B., Manzano,J., Perez,J., De,A.R., 
Gregor,S.J., and Bernal,J. (2001). Thyroid hormone 
regulation of rhes, a novel Ras homolog gene expressed 
in the striatum. Brain Res. Mol. Brain Res. 94, 1-8. 
111.  Vulpe,C.D., Kuo,Y.M., Murphy,T.L., Cowley,L., 
Askwith,C., Libina,N., Gitschier,J., and Anderson,G.J. 
 99
(1999). Hephaestin, a ceruloplasmin homologue 
implicated in intestinal iron transport, is defective 
in the sla mouse. Nat. Genet. 21, 195-199. 
112. Weinstein,D.A., Roy,C.N., Fleming,M.D., Loda,M.F., 
Wolfsdorf,J.I., and Andrews,N.C. (2002). Inappropriate 
expression of hepcidin is associated with iron 
refractory anemia: implications for the anemia of 
chronic disease. Blood 100, 3776-3781. 
113. Williams,A.M. and Enns,C.A. (1991). A mutated 
transferrin receptor lacking asparagine-linked 
glycosylation sites shows reduced functionality and an 
association with binding immunoglobulin protein. J. 
Biol. Chem. 266, 17648-17654. 
114. Williams,A.M. and Enns,C.A. (1993). A region of the C-
terminal portion of the human transferrin receptor 
contains an asparagine-linked glycosylation site 
critical for receptor structure and function. J. Biol. 
Chem. 268, 12780-12786. 
115. Xu,H., Jin,J., DeFelice,L.J., Andrews,N.C., and 
Clapham,D.E. (2004). A spontaneous, recurrent mutation 
in divalent metal transporter-1 exposes a calcium 
entry pathway. PLoS. Biol. 2, E50. 
116. Yamanaka,K., Ishikawa,H., Megumi,Y., Tokunaga,F., 
Kanie,M., Rouault,T.A., Morishima,I., Minato,N., 
Ishimori,K., and Iwai,K. (2003). Identification of the 
ubiquitin-protein ligase that recognizes oxidized 
IRP2. Nat. Cell Biol. 5, 336-340. 
117. Yamashiro,D.J., Tycko,B., Fluss,S.R., and 
Maxfield,F.R. (1984). Segregation of transferrin to a 
mildly acidic (pH 6.5) para-Golgi compartment in the 
recycling pathway. Cell 37, 789-800. 
118. Zak,O., Trinder,D., and Aisen,P. (1994). Primary 
receptor-recognition site of human transferrin is in 
the C-terminal lobe. J. Biol. Chem. 269, 7110-7114. 
119. Zecca,L., Youdim,M.B., Riederer,P., Connor,J.R., and 
Crichton,R.R. (2004). Iron, brain ageing and 
neurodegenerative disorders. Nat. Rev. Neurosci. 5, 
863-873. 
 100
120. Zerial,M., Melancon,P., Schneider,C., and Garoff,H. 
(1986). The transmembrane segment of the human 
transferrin receptor functions as a signal peptide. 
EMBO J. 5, 1543-1550. 
 
 
J A I M E  H .  C H E A H  
EDUCATION 
 
1999 – present     Johns Hopkins School of Medicine          Baltimore, MD 
                                Ph.D. Candidate in Biochemistry, Cellular and 
                                Molecular Biology, Concentration in Neuroscience 
 
1995 – 1999         McGill University                                     Montreal, Quebec 
                               B.Sc. in Biochemistry 
RESEARCH EXPERIENCE 
 
Sept 1999 – present                  Johns Hopkins School of Medicine 
Supervisor: Dr. Solomon H. Snyder 
“Behind the Iron Curtain: Dexras1 mediates Glutamate-NMDA induced 
neuronal iron uptake” 
 Jan 1998 – July 1999               McGill University  
Supervisor: Dr. Alice Vrielink 
“Crystallization and structural determination of L-Amino Acid Oxidase by 
X-ray crystallography” 
 Jan 1997 – August 1997           McGill University  
Supervisor: Dr. Alice Vrielink 
“Crystallization of Cut repeat-3 and homeodomain protein” 
May 1996 – August 1996         Harvard Medical School  
Supervisor: Dr. Tom Ellenberger 
“Site-directed mutagenesis of AlkA and crystallization of EndoV” 
AWARDS  
 May 26, 2005        Biochemical Journal Young Investigators Award 
First Congress of the International BioIron Society, Prague, Czech 
Republic, May 22-27, 2005 
 
June, 2002          Outstanding Preceptor Award  
Johns Hopkins University – Paul Lawrence Dunbar High School 
Partnership 
 
2 3 7  W .  L A N V A L E  S T R E E T ,  B A L T I M O R E ,  M D  2 1 2 1 7  
 
 





1. Cheah JH, Kim SF, Hester LD, Clancy KW, Patterson SE, 
Papadopoulos V and Snyder SH: Glutamate-NMDA receptor-nitric 
oxide transmission mediates neuronal iron homeostasis via the 
GTPase Dexras1. Neuron. 2005 (in revision) 
2. Hara MR, Agrawal N, Kim SF, Cascio MB, Fujimuro M, Ozeki Y, 
Takahashi M, Cheah JH, Tankou SK, Hester LD, Ferris CD, Hayward 
SD, Snyder SH and Sawa A: S-nitrosylated GAPDH initiates apoptotic 
cell death by nuclear translocation following Siah1 binding. Nat Cell 
Biol. 2005,  Jul;7(7):665-74.  
3. Huang Y, Man HY, Sekine-Aizawa Y, Han Y, Juluri K, Luo H, Cheah J, 
Lowenstein C, Huganir RL and Snyder SH: S-nitrosylation of N-
ethylmaleimide sensitive factor mediates surface expression of AMPA 
receptors. Neuron. 2005 May 19;46(4):533-40 
4. Pawelek PD, Cheah J, Coulombe R, Macheroux P, Ghisla S and 
Vrielink A: The structure of L-amino acid oxidase reveals the substrate 
trajectory into an enantiomerically conserved active site. EMBO J. 2000 
Aug 15;19(16):4204-15. 
 
ABSTRACTS FOR ORAL PRESENTATIONS 
 
1. Kim SF, Cheah JH, Hester LD, Clancy KW, Patterson SE, 
Papadopoulos V and Snyder SH: A novel mode of regulating brain iron 
homeostatis. 
First Congress of the International BioIron Society. Prague, Czech 
Republic  May 22-27, 2005  
2. Cheah J, Luo X, Hanle LJ, Ha HC, Wellington CL, Igarashi S, Hester 
LD, Hayden MR, Ross CA, Snyder SH and Sawa A: Influence of 
Huntington toxicity by GAPDH 
Society for Neuroscience, New Orleans, LA  November 4-9, 2000  
 
ABSTRACTS FOR POSTER PRESENTATIONS 
 
1. Cheah JH, Kim SF, Hester LD, Clancy KW, Patterson SE, 
Papadopoulos V and Snyder SH: Dexras1 regulates transferrin-mediated 
iron trafficking in the brain. First Congress of the International BioIron 
Society. Prague, Czech Republic  May 22 - 27, 2005  
2. Cheah JH, Kim SF, Hester LD, Clancy KW, Patterson SE, 
Papadopoulos V and Snyder SH: Dexras1 mediates iron trafficking. 
Society for Neuroscience, San Diego, CA  October 23 - 27, 2004  
3. Cheah JH, Rao M, Penzes P and Snyder SH: Kalirins as modulators of 
Dexras1 activity. Society for Neuroscience, New Orleans, LA  November 8 
– 12, 2003 
4. Kim S, Cheah J and Snyder SH: Heme Oxygenase and Nitric Oxide 
Synthase interaction under stress conditions. Society for Neuroscience, 








2002 - present The Restriction Digest 
                                 The Graduate Student Association Newsletter 
                                 2004-2005: Senior Editor 
                                 2002-present: Editor 
2000 Biochemistry, Cellular and Molecular Biology Lecture 
                                 Invited Speaker: 1995 Nobel Laureate, Dr. Eric 
                                 Wieschaus, Princeton 
2000                        Biochemistry, Cellular and Molecular Biology Big  
                                  Sib/Little Sib Program  
 
ABSTRACTS FOR POSTER PRESENTATIONS (CONTINUED) 
 
5. Huang Y, Man H, Aizawa T, Luo H, Cheah J, Lowenstein C, Huganir 
R and Snyder SH: NMDA-induced relocalization of AMPA receptors into 
membrane raft domains is mediated by S-nitrysolation of NSF.  Society 
for Neuroscience, New Orleans, LA   November 8 – 12, 2003 
6. Watkins CC, Kaplin AI, Rao M, Cheah JH, Boehning D, Benham CA, 
Ferris CD and Snyder SH: Differential roles of neuronal Nitric Oxide 
Synthase and Heme Oxygenase-2 in the proximal and distal 
gastrointestinal pathway correspond to distinct properties of CO and 
NO. Society for Neuroscience, Orlando, FL  November 2 - 7, 20027. 
Dinkova-Kostova AT, Cheah J and Talalay P: Amplification of cellular 
mechanisms for protection against electrophiles and oxidants by Michael 
reaction acceptors. Proceedings of the American Association for Cancer 
Research 43:478, 2002 
8. Cheah JH, Hester LD, Blackshaw S, Sawa A and Snyder SH: Dexras1 
and hippocampal atrophy. Society for Neuroscience, San Diego, CA  









1. Dr. Solomon H. Snyder,  Professor and Director 
    Department of Neuroscience, Johns Hopkins School of Medicine 
    725 N. Wolfe Street, WBS 813, Baltimore, MD 21205 
    Phone: 410-955-3024 
    Fax: 410-955-3623 
    Email: ssnyder@jhmi.edu 
 
2. Dr. Michael J. Caterina, Associate Professor 
    Department of Biological Chemistry  
    Johns Hopkins School of Medicine  
    725 North Wolfe Street , Baltimore, MD  21205  
    Phone: 410-502-5457  
    Fax: 410-955-5759  
    Email: caterina@jhmi.edu 
 
3. Dr. Alice Vrielink, Associate Professor 
    Departments of Biology and Chemistry,  
    University of California-Santa Cruz 
    Sinsheimer Labs, 1156 High Street, Santa Cruz, CA 95064 
    Phone: 813-459-5126 
    Fax: 813-459-3139 
    Email: vrielink@biology.ucsc.edu 
 
4. Dr. Tom Ellenberger, Wittcoff Professor and Head 
    Biochemistry and Molecular Biophysics 
    Washington University School of Medicine 
    660 S. Euclid, Campus Box 8231, St. Louis, MO 63110 
    Phone: 314-747-8893   
    Fax: 314-747-1145 
    Email: tome@wustl.edu 
 
  
